1
|
Bouvet P, de Gea P, Aimard M, Chounlamountri N, Honnorat J, Delcros JG, Salin PA, Meissirel C. A novel peptide derived from vascular endothelial growth factor prevents amyloid beta aggregation and toxicity. Aging Cell 2023; 22:e13907. [PMID: 37415305 PMCID: PMC10497828 DOI: 10.1111/acel.13907] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 05/10/2023] [Accepted: 06/05/2023] [Indexed: 07/08/2023] Open
Abstract
Amyloid-β oligomers (Aβo) are the most pathologically relevant Aβ species in Alzheimer's disease (AD), because they induce early synaptic dysfunction that leads to learning and memory impairments. In contrast, increasing VEGF (Vascular Endothelial Growth Factor) brain levels have been shown to improve learning and memory processes, and to alleviate Aβ-mediated synapse dysfunction. Here, we designed a new peptide, the blocking peptide (BP), which is derived from an Aβo-targeted domain of the VEGF protein, and investigated its effect on Aβ-associated toxicity. Using a combination of biochemical, 3D and ultrastructural imaging, and electrophysiological approaches, we demonstrated that BP strongly interacts with Aβo and blocks Aβ fibrillar aggregation process, leading to the formation of Aβ amorphous aggregates. BP further impedes the formation of structured Aβo and prevents their pathogenic binding to synapses. Importantly, acute BP treatment successfully rescues long-term potentiation (LTP) in the APP/PS1 mouse model of AD, at an age when LTP is highly impaired in hippocampal slices. Moreover, BP is also able to block the interaction between Aβo and VEGF, which suggests a dual mechanism aimed at both trapping Aβo and releasing VEGF to alleviate Aβo-induced synaptic damage. Our findings provide evidence for a neutralizing effect of the BP on Aβ aggregation process and pathogenic action, highlighting a potential new therapeutic strategy.
Collapse
Affiliation(s)
- P. Bouvet
- MeLiS, Institut NeuroMyoGène (INMG), Synaptopathies and Autoantibodies, Institut National de la Santé et de la Recherche Médicale (INSERM), U1314Centre National de la Recherche Scientifique (CNRS), UMR5284LyonFrance
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
| | - P. de Gea
- MeLiS, Institut NeuroMyoGène (INMG), Synaptopathies and Autoantibodies, Institut National de la Santé et de la Recherche Médicale (INSERM), U1314Centre National de la Recherche Scientifique (CNRS), UMR5284LyonFrance
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
| | - M. Aimard
- MeLiS, Institut NeuroMyoGène (INMG), Synaptopathies and Autoantibodies, Institut National de la Santé et de la Recherche Médicale (INSERM), U1314Centre National de la Recherche Scientifique (CNRS), UMR5284LyonFrance
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
| | - N. Chounlamountri
- MeLiS, Institut NeuroMyoGène (INMG), Synaptopathies and Autoantibodies, Institut National de la Santé et de la Recherche Médicale (INSERM), U1314Centre National de la Recherche Scientifique (CNRS), UMR5284LyonFrance
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
| | - J. Honnorat
- MeLiS, Institut NeuroMyoGène (INMG), Synaptopathies and Autoantibodies, Institut National de la Santé et de la Recherche Médicale (INSERM), U1314Centre National de la Recherche Scientifique (CNRS), UMR5284LyonFrance
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
| | - J. G. Delcros
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
- Centre de Recherche en Cancérologie de Lyon, Apoptosis, Cancer and Development, Institut PLAsCAN, INSERM U1052, CNRS UMR5286Centre Léon BérardLyonFrance
- Centre de Recherche en Cancérologie de Lyon, Small Molecules for Biological TargetsINSERM U1052 – CNRS UMR5286, ISPB RockefellerLyonFrance
| | - P. A. Salin
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
- Centre de Recherche en Neurosciences de Lyon, Forgetting Processes and Cortical DynamicsINSERM U1028, CNRS UMR5292BronFrance
| | - C. Meissirel
- MeLiS, Institut NeuroMyoGène (INMG), Synaptopathies and Autoantibodies, Institut National de la Santé et de la Recherche Médicale (INSERM), U1314Centre National de la Recherche Scientifique (CNRS), UMR5284LyonFrance
- Univ LyonUniversité Claude Bernard Lyon 1LyonFrance
| |
Collapse
|
2
|
Ponzo M, Debesset A, Cossutta M, Chalabi-Dchar M, Houppe C, Pilon C, Nicolas-Boluda A, Meunier S, Raineri F, Thiolat A, Nicolle R, Maione F, Brundu S, Cojocaru CF, Bouvet P, Bousquet C, Gazeau F, Tournigand C, Courty J, Giraudo E, Cohen JL, Cascone I. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022 , 14, 4265. Cancers (Basel) 2022; 14:cancers14246160. [PMID: 36551754 PMCID: PMC9776549 DOI: 10.3390/cancers14246160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 11/23/2022] [Indexed: 12/15/2022] Open
Abstract
In the original publication [...].
Collapse
Affiliation(s)
- Matteo Ponzo
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Anais Debesset
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Mélissande Cossutta
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Mounira Chalabi-Dchar
- Cancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France
| | - Claire Houppe
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Caroline Pilon
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Alba Nicolas-Boluda
- Matières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France
| | - Sylvain Meunier
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Fabio Raineri
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Allan Thiolat
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Rémy Nicolle
- Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, F-75013 Paris, France
| | - Federica Maione
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Serena Brundu
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Carina Florina Cojocaru
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Philippe Bouvet
- Matières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France
- Ecole Normale Supérieure de Lyon, University of Lyon, F-69342 Lyon, France
| | - Corinne Bousquet
- UMR INSERM-1037, Cancer Research Center of Toulouse (CRCT), Toulouse University III, F-31037 Toulouse, France
| | - Florence Gazeau
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Christophe Tournigand
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Service d’Oncologie Médicale, Groupe Hospitalo-Universitaire Chenevier Mondor, F-94010 Créteil, France
| | - José Courty
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- Cancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France
| | - Enrico Giraudo
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - José L. Cohen
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Ilaria Cascone
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
- Correspondence: ; Tel.: +33-149-813-765
| |
Collapse
|
3
|
Fabre L, Rousset C, Monier K, Da Cruz-Boisson F, Bouvet P, Charreyre MT, Delair T, Fleury E, Favier A. Fluorescent Polymer-AS1411-Aptamer Probe for dSTORM Super-Resolution Imaging of Endogenous Nucleolin. Biomacromolecules 2022; 23:2302-2314. [PMID: 35549176 DOI: 10.1021/acs.biomac.1c01706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Nucleolin is a multifunctional protein involved in essential biological processes. To precisely localize it and unravel its different roles in cells, fluorescence imaging is a powerful tool, especially super-resolution techniques. Here, we developed polymer-aptamer probes, both small and bright, adapted to direct stochastic optical reconstruction microscopy (dSTORM). Well-defined fluorescent polymer chains bearing fluorophores (AlexaFluor647) and a reactive end group were prepared via RAFT polymerization. The reactive end-group was then used for the oriented conjugation with AS1411, a DNA aptamer that recognizes nucleolin with high affinity. Conjugation via strain-promoted alkyne/azide click chemistry (SPAAC) between dibenzylcyclooctyne-ended fluorescent polymer chains and 3'-azido-functionalized nucleic acids proved to be the most efficient approach. In vitro and in cellulo evaluations demonstrated that selective recognition for nucleolin was retained. Their brightness and small size make these polymer-aptamer probes an appealing alternative to immunofluorescence, especially for super-resolution (10-20 nm) nanoscopy. dSTORM imaging demonstrated the ability of our fluorescent polymer-aptamer probe to provide selective and super-resolved detection of cell surface nucleolin.
Collapse
Affiliation(s)
- Laura Fabre
- Univ Lyon, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Université Claude Bernard Lyon 1, INSA Lyon, F-69622 Villeurbanne Cédex, France
| | - Corentin Rousset
- Univ Lyon, Centre Léon Bérard, UMR INSERM 1052 CNRS 5286, Centre de recherche en cancérologie de Lyon, Lyon F-69008, France
| | - Karine Monier
- Univ Lyon, Centre Léon Bérard, UMR INSERM 1052 CNRS 5286, Centre de recherche en cancérologie de Lyon, Lyon F-69008, France
| | - Fernande Da Cruz-Boisson
- Univ Lyon, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Université Claude Bernard Lyon 1, INSA Lyon, F-69622 Villeurbanne Cédex, France
| | - Philippe Bouvet
- Univ Lyon, Centre Léon Bérard, UMR INSERM 1052 CNRS 5286, Centre de recherche en cancérologie de Lyon, Lyon F-69008, France
| | - Marie-Thérèse Charreyre
- Univ Lyon, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Université Claude Bernard Lyon 1, INSA Lyon, F-69622 Villeurbanne Cédex, France
| | - Thierry Delair
- Univ Lyon, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Université Claude Bernard Lyon 1, INSA Lyon, F-69622 Villeurbanne Cédex, France
| | - Etienne Fleury
- Univ Lyon, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Université Claude Bernard Lyon 1, INSA Lyon, F-69622 Villeurbanne Cédex, France
| | - Arnaud Favier
- Univ Lyon, CNRS, UMR 5223, Ingénierie des Matériaux Polymères, Université Claude Bernard Lyon 1, INSA Lyon, F-69622 Villeurbanne Cédex, France
| |
Collapse
|
4
|
Therizols G, Bash-Imam Z, Panthu B, Machon C, Vincent A, Ripoll J, Nait-Slimane S, Chalabi-Dchar M, Gaucherot A, Garcia M, Laforêts F, Marcel V, Boubaker-Vitre J, Monet MA, Bouclier C, Vanbelle C, Souahlia G, Berthel E, Albaret MA, Mertani HC, Prudhomme M, Bertrand M, David A, Saurin JC, Bouvet P, Rivals E, Ohlmann T, Guitton J, Dalla Venezia N, Pannequin J, Catez F, Diaz JJ. Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance. Nat Commun 2022; 13:173. [PMID: 35013311 PMCID: PMC8748862 DOI: 10.1038/s41467-021-27847-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Accepted: 12/10/2021] [Indexed: 02/06/2023] Open
Abstract
Mechanisms of drug-tolerance remain poorly understood and have been linked to genomic but also to non-genomic processes. 5-fluorouracil (5-FU), the most widely used chemotherapy in oncology is associated with resistance. While prescribed as an inhibitor of DNA replication, 5-FU alters all RNA pathways. Here, we show that 5-FU treatment leads to the production of fluorinated ribosomes exhibiting altered translational activities. 5-FU is incorporated into ribosomal RNAs of mature ribosomes in cancer cell lines, colorectal xenografts, and human tumors. Fluorinated ribosomes appear to be functional, yet, they display a selective translational activity towards mRNAs depending on the nature of their 5'-untranslated region. As a result, we find that sustained translation of IGF-1R mRNA, which encodes one of the most potent cell survival effectors, promotes the survival of 5-FU-treated colorectal cancer cells. Altogether, our results demonstrate that "man-made" fluorinated ribosomes favor the drug-tolerant cellular phenotype by promoting translation of survival genes.
Collapse
MESH Headings
- Antimetabolites, Antineoplastic/pharmacology
- Cell Line, Tumor
- Cell Survival/drug effects
- Colorectal Neoplasms/drug therapy
- Colorectal Neoplasms/genetics
- Colorectal Neoplasms/metabolism
- Colorectal Neoplasms/pathology
- DNA Replication
- DNA, Neoplasm/genetics
- DNA, Neoplasm/metabolism
- Drug Resistance, Neoplasm/genetics
- Drug Tolerance/genetics
- Fluorouracil/pharmacology
- HCT116 Cells
- Halogenation
- Humans
- Protein Biosynthesis/drug effects
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Ribosomal/genetics
- RNA, Ribosomal/metabolism
- Receptor, IGF Type 1/agonists
- Receptor, IGF Type 1/genetics
- Receptor, IGF Type 1/metabolism
- Ribosomes/drug effects
- Ribosomes/genetics
- Ribosomes/metabolism
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Gabriel Therizols
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Zeina Bash-Imam
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Baptiste Panthu
- CIRI-Inserm U1111, Ecole Normale Supérieure de Lyon, Lyon, F-693643, France
- Inserm U1060, CARMEN, F-69310, Pierre Bénite, France
| | - Christelle Machon
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
- Laboratoire de chimie analytique, Faculté de pharmacie de Lyon, 8 avenue Rockefeller, F-69373, Lyon, France
- Laboratoire de biochimie et de pharmaco-toxicologie, Centre hospitalier Lyon-Sud - HCL, F-69495, Pierre Bénite, France
| | - Anne Vincent
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Julie Ripoll
- LIRMM, UMR 5506, University of Montpellier, CNRS, Montpellier, France
| | - Sophie Nait-Slimane
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Mounira Chalabi-Dchar
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Angéline Gaucherot
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Maxime Garcia
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Florian Laforêts
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Virginie Marcel
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | | | - Marie-Ambre Monet
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | | | - Christophe Vanbelle
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Guillaume Souahlia
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Elise Berthel
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Marie Alexandra Albaret
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
- Department of Translational Research and Innovation, Centre Léon Bérard, 69373, Lyon, France
| | - Hichem C Mertani
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | - Michel Prudhomme
- Department of Digestive Surgery, CHU Nimes, Univ Montpellier, Nimes, France
| | - Martin Bertrand
- Department of Digestive Surgery, CHU Nimes, Univ Montpellier, Nimes, France
| | - Alexandre David
- IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France
- IRMB-PPC, Univ Montpellier, INSERM, CHU Montpellier, CNRS, Montpellier, France
| | - Jean-Christophe Saurin
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
- Department of Endoscopy and Gastroenterology, Pavillon L, Edouard Herriot Hospital, Lyon, France
| | - Philippe Bouvet
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
- Ecole Normale Supérieure de Lyon, Lyon, France
| | - Eric Rivals
- LIRMM, UMR 5506, University of Montpellier, CNRS, Montpellier, France
- Institut Français de Bioinformatique, CNRS UMS 3601, Évry, France
| | - Théophile Ohlmann
- CIRI-Inserm U1111, Ecole Normale Supérieure de Lyon, Lyon, F-693643, France
| | - Jérôme Guitton
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
- Laboratoire de biochimie et de pharmaco-toxicologie, Centre hospitalier Lyon-Sud - HCL, F-69495, Pierre Bénite, France
- Laboratoire de toxicologie, Faculté de pharmacie de Lyon, Université de Lyon, 8 avenue Rockefeller, F-69373, Lyon, France
| | - Nicole Dalla Venezia
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France
- Centre Léon Bérard, F-69008, Lyon, France
- Université de Lyon 1, F-69000, Lyon, France
| | | | - Frédéric Catez
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.
- Centre Léon Bérard, F-69008, Lyon, France.
- Université de Lyon 1, F-69000, Lyon, France.
- Institut Convergence PLAsCAN, F-69373, Lyon, France.
| | - Jean-Jacques Diaz
- Inserm U1052, CNRS UMR5286 Centre de Recherche en Cancérologie de Lyon, F-69000, Lyon, France.
- Centre Léon Bérard, F-69008, Lyon, France.
- Université de Lyon 1, F-69000, Lyon, France.
- Institut Convergence PLAsCAN, F-69373, Lyon, France.
| |
Collapse
|
5
|
Chalabi-Dchar M, Cruz E, Mertani HC, Diaz JJ, Courty J, Cascone I, Bouvet P. Nucleolin Aptamer N6L Reprograms the Translational Machinery and Acts Synergistically with mTORi to Inhibit Pancreatic Cancer Proliferation. Cancers (Basel) 2021; 13:cancers13194957. [PMID: 34638443 PMCID: PMC8508287 DOI: 10.3390/cancers13194957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 09/15/2021] [Accepted: 09/26/2021] [Indexed: 11/25/2022] Open
Abstract
Simple Summary Pancreatic cancer is an aggressive disease characterized by its invasiveness, rapid progression, and resistance to conventional therapy. There is a need to identify new molecules to improve current therapies. The aim of this study was to analyze how the pancreatic cancer cells react to the treatment with an inhibitor of nucleolin, N6L. To this end, we analyzed how the translation was affected in the cells during the treatment. We discovered that in response to N6L, a signaling pathway called the mTOR pathway was activated and was involved in the activation of translation of a subset of mRNA that could be involved in the resistance of the cells to the treatment. Indeed, we showed that the combined action of inhibitors of the mTOR pathway with N6L synergistically inhibited the cancer cells’ proliferation. We propose that this new combination of molecules could be a novel therapeutic option for pancreatic cancer. Abstract We previously showed that N6L, a pseudopeptide that targets nucleolin, impairs pancreatic ductal adenocarcinoma (PDAC) growth and normalizes tumor vessels in animal models. In this study, we analyzed the translatome of PDAC cells treated with N6L to identify the pathways that were either repressed or activated. We observed a strong decrease in global protein synthesis. However, about 6% of the mRNAs were enriched in the polysomes. We identified a 5′TOP motif in many of these mRNAs and demonstrated that a chimeric RNA bearing a 5‘TOP motif was up-regulated by N6L. We demonstrated that N6L activates the mTOR pathway, which is required for the translation of these mRNAs. An inhibitory synergistic effect in PDAC cell lines, including patient-derived xenografts and tumor-derived organoids, was observed when N6L was combined with mTOR inhibitors. In conclusion, N6L reduces pancreatic cells proliferation, which then undergoes translational reprogramming through activation of the mTOR pathway. N6L and mTOR inhibitors act synergistically to inhibit the proliferation of PDAC and human PDX cell lines. This combotherapy of N6L and mTOR inhibitors could constitute a promising alternative to treat pancreatic cancer.
Collapse
Affiliation(s)
- Mounira Chalabi-Dchar
- Centre de Recherche en Cancérologie de Lyon, Université de Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, CEDEX 08, F-69373 Lyon, France; (M.C.-D.); (E.C.); (H.C.M.); (J.-J.D.)
| | - Elisabeth Cruz
- Centre de Recherche en Cancérologie de Lyon, Université de Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, CEDEX 08, F-69373 Lyon, France; (M.C.-D.); (E.C.); (H.C.M.); (J.-J.D.)
| | - Hichem C. Mertani
- Centre de Recherche en Cancérologie de Lyon, Université de Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, CEDEX 08, F-69373 Lyon, France; (M.C.-D.); (E.C.); (H.C.M.); (J.-J.D.)
| | - Jean-Jacques Diaz
- Centre de Recherche en Cancérologie de Lyon, Université de Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, CEDEX 08, F-69373 Lyon, France; (M.C.-D.); (E.C.); (H.C.M.); (J.-J.D.)
| | - José Courty
- INSERM, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil, F-94010 Créteil, France; (J.C.); (I.C.)
| | - Ilaria Cascone
- INSERM, Institut Mondor de Recherche Biomédicale (IMRB), Université Paris-Est Créteil, F-94010 Créteil, France; (J.C.); (I.C.)
| | - Philippe Bouvet
- Centre de Recherche en Cancérologie de Lyon, Université de Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, CEDEX 08, F-69373 Lyon, France; (M.C.-D.); (E.C.); (H.C.M.); (J.-J.D.)
- Ecole Normale Supérieure de Lyon, Université de Lyon 1, F-69007 Lyon, France
- Correspondence:
| |
Collapse
|
6
|
Chalabi-Dchar M, Fenouil T, Machon C, Vincent A, Catez F, Marcel V, Mertani HC, Saurin JC, Bouvet P, Guitton J, Venezia ND, Diaz JJ. A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate. NAR Cancer 2021; 3:zcab032. [PMID: 34409299 PMCID: PMC8364333 DOI: 10.1093/narcan/zcab032] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2021] [Revised: 07/01/2021] [Accepted: 08/09/2021] [Indexed: 12/24/2022] Open
Abstract
5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat patients with solid tumours, such as colorectal and pancreatic cancers. Colorectal cancer (CRC) is the second leading cause of cancer-related death and half of patients experience tumour recurrence. Used for over 60 years, 5-FU was long thought to exert its cytotoxic effects by altering DNA metabolism. However, 5-FU mode of action is more complex than previously anticipated since 5-FU is an extrinsic source of RNA modifications through its ability to be incorporated into most classes of RNA. In particular, a recent report highlighted that, by its integration into the most abundant RNA, namely ribosomal RNA (rRNA), 5-FU creates fluorinated active ribosomes and induces translational reprogramming. Here, we review the historical knowledge of 5-FU mode of action and discuss progress in the field of 5-FU-induced RNA modifications. The case of rRNA, the essential component of ribosome and translational activity, and the plasticity of which was recently associated with cancer, is highlighted. We propose that translational reprogramming, induced by 5-FU integration in ribosomes, contributes to 5-FU-driven cell plasticity and ultimately to relapse.
Collapse
Affiliation(s)
- Mounira Chalabi-Dchar
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Tanguy Fenouil
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Christelle Machon
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Anne Vincent
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Frédéric Catez
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Virginie Marcel
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Hichem C Mertani
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Jean-Christophe Saurin
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Philippe Bouvet
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Jérôme Guitton
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Nicole Dalla Venezia
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| | - Jean-Jacques Diaz
- Inserm U1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Centre Léon Bérard, F-69373 Lyon Cedex 08, France
| |
Collapse
|
7
|
Raineri F, Bourgoin-Voillard S, Cossutta M, Habert D, Ponzo M, Houppe C, Vallée B, Boniotto M, Chalabi-Dchar M, Bouvet P, Couvelard A, Cros J, Debesset A, Cohen JL, Courty J, Cascone I. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021; 13:cancers13122986. [PMID: 34203710 PMCID: PMC8232280 DOI: 10.3390/cancers13122986] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Revised: 06/08/2021] [Accepted: 06/10/2021] [Indexed: 01/03/2023] Open
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and resistant cancer with no available effective therapy. We have previously demonstrated that nucleolin targeting by N6L impairs tumor growth and normalizes tumor vessels in PDAC mouse models. Here, we investigated new pathways that are regulated by nucleolin in PDAC. We found that N6L and nucleolin interact with β-catenin. We found that the Wnt/β-catenin pathway is activated in PDAC and is necessary for tumor-derived 3D growth. N6L and nucleolin loss of function induced by siRNA inhibited Wnt pathway activation by preventing β-catenin stabilization in PDAC cells. N6L also inhibited the growth and the activation of the Wnt/β-catenin pathway in vivo in mice and in 3D cultures derived from MIA PaCa2 tumors. On the other hand, nucleolin overexpression increased β-catenin stabilization. In conclusion, in this study, we identified β-catenin as a new nucleolin interactor and suggest that the Wnt/β-catenin pathway could be a new target of the nucleolin antagonist N6L in PDAC.
Collapse
Affiliation(s)
- Fabio Raineri
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Sandrine Bourgoin-Voillard
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- University of Grenoble Alpes, CNRS, Grenoble INP, Inserm U1055, LBFA and BEeSy, PROMETHEE Proteomic Platform, 38400 Saint-Martin d’Heres, France
- University of Grenoble Alpes, CNRS, Grenoble INP, TIMC, PROMETHEE Proteomic Platform, 38000 Grenoble, France
- CHU Grenoble Alpes, Institut de Biologie et de Pathologie, 38043 Grenoble, France
| | - Mélissande Cossutta
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
| | - Damien Habert
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Matteo Ponzo
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Claire Houppe
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Benoît Vallée
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Michele Boniotto
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - Mounira Chalabi-Dchar
- Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 69008 Lyon, France; (M.C.-D.); (P.B.)
| | - Philippe Bouvet
- Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, 69008 Lyon, France; (M.C.-D.); (P.B.)
- University of Lyon, Ecole Normale Supérieure de Lyon, 69342 Lyon, France
| | - Anne Couvelard
- Département de Pathologie, Hôpital Bichat APHP DHU UNITY, 75018 Paris, France; (A.C.); (J.C.)
| | - Jerome Cros
- Département de Pathologie, Hôpital Bichat APHP DHU UNITY, 75018 Paris, France; (A.C.); (J.C.)
| | - Anais Debesset
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
| | - José L. Cohen
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
| | - José Courty
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
| | - Ilaria Cascone
- University Paris Est Créteil, INSERM, IMRB, 94010 Créteil, France; (F.R.); (S.B.-V.); (M.C.); (D.H.); (M.P.); (C.H.); (B.V.); (M.B.); (A.D.); (J.L.C.); (J.C.)
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre d’Investigation Clinique Biotherapie, 94010 Créteil, France
- Correspondence: ; Tel.: +33-149-813-765
| |
Collapse
|
8
|
Ochiai K, Yamaoka M, Swaminathan A, Shima H, Hiura H, Matsumoto M, Kurotaki D, Nakabayashi J, Funayama R, Nakayama K, Arima T, Ikawa T, Tamura T, Sciammas R, Bouvet P, Kundu TK, Igarashi K. Chromatin Protein PC4 Orchestrates B Cell Differentiation by Collaborating with IKAROS and IRF4. Cell Rep 2020; 33:108517. [PMID: 33357426 DOI: 10.1016/j.celrep.2020.108517] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 10/10/2020] [Accepted: 11/22/2020] [Indexed: 12/24/2022] Open
Abstract
The chromatin protein positive coactivator 4 (PC4) has multiple functions, including chromatin compaction. However, its role in immune cells is largely unknown. We show that PC4 orchestrates chromatin structure and gene expression in mature B cells. B-cell-specific PC4-deficient mice show impaired production of antibody upon antigen stimulation. The PC4 complex purified from B cells contains the transcription factors (TFs) IKAROS and IRF4. IKAROS protein is reduced in PC4-deficient mature B cells, resulting in de-repression of their target genes in part by diminished interactions with gene-silencing components. Upon activation, the amount of IRF4 protein is not increased in PC4-deficient B cells, resulting in reduction of plasma cells. Importantly, IRF4 reciprocally induces PC4 expression via a super-enhancer. PC4 knockdown in human B cell lymphoma and myeloma cells reduces IKAROS protein as an anticancer drug, lenalidomide. Our findings establish PC4 as a chromatin regulator of B cells and a possible therapeutic target adjoining IKAROS in B cell malignancies.
Collapse
Affiliation(s)
- Kyoko Ochiai
- Department of Biochemistry, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan.
| | - Mari Yamaoka
- Department of Biochemistry, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan
| | - Amrutha Swaminathan
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - Hiroki Shima
- Department of Biochemistry, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan
| | - Hitoshi Hiura
- Department of Informative Genetics, Environment and Genome Research Center, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan
| | - Mitsuyo Matsumoto
- Department of Biochemistry, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan; Center for Regulatory Epigenome and Diseases, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan
| | - Daisuke Kurotaki
- Department of Immunology, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Yokohama 236-0004, Japan
| | - Jun Nakabayashi
- Advanced Medical Research Center, Yokohama City University, Fukuura 3-9, Yokohama 236-0004, Japan
| | - Ryo Funayama
- Center for Regulatory Epigenome and Diseases, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan; Division of Cell Proliferation, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan
| | - Keiko Nakayama
- Center for Regulatory Epigenome and Diseases, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan; Division of Cell Proliferation, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan
| | - Takahiro Arima
- Department of Informative Genetics, Environment and Genome Research Center, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan
| | - Tomokatsu Ikawa
- Division of Immunobiology, Tokyo University of Science, Yamazaki 2669, Noda 278-0022, Japan
| | - Tomohiko Tamura
- Department of Immunology, Yokohama City University Graduate School of Medicine, Fukuura 3-9, Yokohama 236-0004, Japan; Advanced Medical Research Center, Yokohama City University, Fukuura 3-9, Yokohama 236-0004, Japan
| | - Roger Sciammas
- Center for Immunology and Infectious Diseases, University of California Davis, Davis, CA 95616, USA
| | - Philippe Bouvet
- Université de Lyon, Ecole Normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Tapas K Kundu
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India.
| | - Kazuhiko Igarashi
- Department of Biochemistry, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan; Center for Regulatory Epigenome and Diseases, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Sendai 980-8575, Japan.
| |
Collapse
|
9
|
Nait Slimane S, Marcel V, Fenouil T, Catez F, Saurin JC, Bouvet P, Diaz JJ, Mertani HC. Ribosome Biogenesis Alterations in Colorectal Cancer. Cells 2020; 9:E2361. [PMID: 33120992 PMCID: PMC7693311 DOI: 10.3390/cells9112361] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Revised: 10/23/2020] [Accepted: 10/25/2020] [Indexed: 12/24/2022] Open
Abstract
Many studies have focused on understanding the regulation and functions of aberrant protein synthesis in colorectal cancer (CRC), leaving the ribosome, its main effector, relatively underappreciated in CRC. The production of functional ribosomes is initiated in the nucleolus, requires coordinated ribosomal RNA (rRNA) processing and ribosomal protein (RP) assembly, and is frequently hyperactivated to support the needs in protein synthesis essential to withstand unremitting cancer cell growth. This elevated ribosome production in cancer cells includes a strong alteration of ribosome biogenesis homeostasis that represents one of the hallmarks of cancer cells. None of the ribosome production steps escape this cancer-specific dysregulation. This review summarizes the early and late steps of ribosome biogenesis dysregulations described in CRC cell lines, intestinal organoids, CRC stem cells and mouse models, and their possible clinical implications. We highlight how this cancer-related ribosome biogenesis, both at quantitative and qualitative levels, can lead to the synthesis of ribosomes favoring the translation of mRNAs encoding hyperproliferative and survival factors. We also discuss whether cancer-related ribosome biogenesis is a mere consequence of cancer progression or is a causal factor in CRC, and how altered ribosome biogenesis pathways can represent effective targets to kill CRC cells. The association between exacerbated CRC cell growth and alteration of specific steps of ribosome biogenesis is highlighted as a key driver of tumorigenesis, providing promising perspectives for the implementation of predictive biomarkers and the development of new therapeutic drugs.
Collapse
Affiliation(s)
- Sophie Nait Slimane
- Cancer Initiation and Tumor Cell Identity, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, 69008 Lyon, France; (S.N.S.); (V.M.); (F.C.); (P.B.)
| | - Virginie Marcel
- Cancer Initiation and Tumor Cell Identity, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, 69008 Lyon, France; (S.N.S.); (V.M.); (F.C.); (P.B.)
| | - Tanguy Fenouil
- Institute of Pathology EST, Hospices Civils de Lyon, Site-Est Groupement Hospitalier- Est, 69677 Bron, France;
| | - Frédéric Catez
- Cancer Initiation and Tumor Cell Identity, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, 69008 Lyon, France; (S.N.S.); (V.M.); (F.C.); (P.B.)
| | - Jean-Christophe Saurin
- Gastroenterology and Genetic Department, Edouard Herriot Hospital, Hospices Civils de Lyon, 69008 Lyon, France;
| | - Philippe Bouvet
- Cancer Initiation and Tumor Cell Identity, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, 69008 Lyon, France; (S.N.S.); (V.M.); (F.C.); (P.B.)
| | - Jean-Jacques Diaz
- Cancer Initiation and Tumor Cell Identity, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, 69008 Lyon, France; (S.N.S.); (V.M.); (F.C.); (P.B.)
| | - Hichem C. Mertani
- Cancer Initiation and Tumor Cell Identity, Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Inserm U1052, CNRS UMR5286 Centre Léon Bérard, 69008 Lyon, France; (S.N.S.); (V.M.); (F.C.); (P.B.)
| |
Collapse
|
10
|
Charignon E, Bouché M, Clave-Darcissac C, Dahm G, Ichim G, Clotagatide A, Mertani HC, Telouk P, Caramel J, Diaz JJ, Bellemin-Laponnaz S, Bouvet P, Billotey C. In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma. Int J Mol Sci 2020; 21:E7826. [PMID: 33105692 PMCID: PMC7659946 DOI: 10.3390/ijms21217826] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Revised: 10/08/2020] [Accepted: 10/19/2020] [Indexed: 02/02/2023] Open
Abstract
We describe here the evaluation of the cytotoxic efficacy of two platinum (II) complexes bearing an N-heterocyclic carbene (NHC) ligand, a pyridine ligand and bromide or iodide ligands on a panel of human metastatic cutaneous melanoma cell lines representing different genetic subsets including BRAF-inhibitor-resistant cell lines, namely A375, SK-MEL-28, MeWo, HMCB, A375-R, SK-MEL-5-R and 501MEL-R. Cisplatin and dacarbazine were also studied for comparison purposes. Remarkably, the iodine-labelled Pt-NHC complex strongly inhibited proliferation of all tested melanoma cells after 1-h exposure, likely due to its rapid uptake by melanoma cells. The mechanism of this inhibitory activity involves the formation of DNA double-strand breaks and apoptosis. Considering the intrinsic chemoresistance of metastatic melanoma cells of current systemic treatments, these findings are promising and could give research opportunities in the future to improve the prognosis of patients suffering from unresectable metastatic melanoma that are not eligible or that do not respond to the most effective drugs available to date, namely BRAF inhibitors and the anti-PD-1 monoclonal antibody (mAb).
Collapse
Affiliation(s)
- Elsa Charignon
- Hospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Université Jean Monnet-Université Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France; (E.C.); (C.C.-D.); (A.C.)
- INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France; (H.C.M.); (J.C.); (J.-J.D.); (P.B.)
| | - Mathilde Bouché
- Institut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg-CNRS UMR7504, Strasbourg, Bâtiment 69, 23 Rue du Loess, 67200 Strasbourg, France; (M.B.); (G.D.); (S.B.-L.)
| | - Caroline Clave-Darcissac
- Hospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Université Jean Monnet-Université Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France; (E.C.); (C.C.-D.); (A.C.)
- Hôpital Nord, Département de Pharmacie, Centre Hospitalier Universitaire de Saint-Etienne, Avenue Albert Raimond, 42270 Saint-Priest, France
| | - Georges Dahm
- Institut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg-CNRS UMR7504, Strasbourg, Bâtiment 69, 23 Rue du Loess, 67200 Strasbourg, France; (M.B.); (G.D.); (S.B.-L.)
| | - Gabriel Ichim
- Cancer Cell Death Laboratory, part of LabEx DEVweCAN, Cancer Initiation and Tumoral Cell Identity Department, Centre de Recherche en Cancérologie de Lyon, 69008 Lyon, France;
| | - Anthony Clotagatide
- Hospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Université Jean Monnet-Université Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France; (E.C.); (C.C.-D.); (A.C.)
- Hôpital Nord, Département de Pharmacie, Centre Hospitalier Universitaire de Saint-Etienne, Avenue Albert Raimond, 42270 Saint-Priest, France
| | - Hichem C. Mertani
- INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France; (H.C.M.); (J.C.); (J.-J.D.); (P.B.)
| | - Philippe Telouk
- Laboratoire de Géologie de Lyon Terre, Planètes, Université de Lyon, Environnement-ENS-UCBL-CNRS, UMR CNRS 5276 (CNRS, ENS, Université Lyon1), École Normale Supérieure de Lyon, 9 rue du Vercors, CEDEX 07, 69364 Lyon, France;
| | - Julie Caramel
- INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France; (H.C.M.); (J.C.); (J.-J.D.); (P.B.)
| | - Jean-Jacques Diaz
- INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France; (H.C.M.); (J.C.); (J.-J.D.); (P.B.)
| | - Stéphane Bellemin-Laponnaz
- Institut de Physique et Chimie des Matériaux de Strasbourg, Université de Strasbourg-CNRS UMR7504, Strasbourg, Bâtiment 69, 23 Rue du Loess, 67200 Strasbourg, France; (M.B.); (G.D.); (S.B.-L.)
| | - Philippe Bouvet
- INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France; (H.C.M.); (J.C.); (J.-J.D.); (P.B.)
- École Normale Supérieure de Lyon, Université de Lyon, 9 rue du Vercors, CEDEX 07, 69364 Lyon, France
| | - Claire Billotey
- INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Université de Lyon, Université Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France; (H.C.M.); (J.C.); (J.-J.D.); (P.B.)
- UFR de Médecine, Campus Santé Innovations, Université de Lyon, Université Jean Monnet, 10 rue de Marandière, 42270 Saint-Priest en Jarez, France
| |
Collapse
|
11
|
Kabirian-Dehkordi S, Chalabi-Dchar M, Mertani HC, Le Guellec D, Verrier B, Diaz JJ, Mehrgardi MA, Bouvet P. AS1411-conjugated gold nanoparticles affect cell proliferation through a mechanism that seems independent of nucleolin. Nanomedicine 2019; 21:102060. [PMID: 31336175 DOI: 10.1016/j.nano.2019.102060] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 06/11/2019] [Accepted: 06/26/2019] [Indexed: 12/15/2022]
Abstract
G-rich oligonucleotide, AS1411, has been shown to interact with nucleolin and to inhibit cancer cell proliferation and tumor growth. This antiproliferative action is increased when AS1411 is conjugated to different types of nanoparticles. However, the molecular mechanisms are not known. In this work, we show in several cell lines that optimized AS1411-conjugated gold nanoparticles (GNS-AS1411) inhibit nucleolin expression at the RNA and protein levels. We observed an alteration of the nucleolar structure with a decrease of ribosomal RNA accumulation comparable to what is observed upon nucleolin knock down. However, the expression of genes involved in cell cycle and the cell cycle blockage by GNS-AS1411 are not regulated in the same way as that in cells where nucleolin has been knocked down. These data suggest that the anti-proliferative activity of GNS-AS1411 is not the only consequence of nucleolin targeting and down-regulation.
Collapse
Affiliation(s)
- Samaneh Kabirian-Dehkordi
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre, Léon Bérard, Lyon, France; Department of chemistry, University of Isfahan, Isfahan, Iran
| | - Mounira Chalabi-Dchar
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre, Léon Bérard, Lyon, France
| | - Hichem C Mertani
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre, Léon Bérard, Lyon, France
| | - Dominique Le Guellec
- Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, Université Claude Bernard Lyon 1, Centre, National de la Recherche Scientifique (CNRS), Lyon, France
| | - Bernard Verrier
- Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, Université Claude Bernard Lyon 1, Centre, National de la Recherche Scientifique (CNRS), Lyon, France
| | - Jean-Jacques Diaz
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre, Léon Bérard, Lyon, France
| | | | - Philippe Bouvet
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre, Léon Bérard, Lyon, France; Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France.
| |
Collapse
|
12
|
Nguyen Van Long F, Lardy-Cleaud A, Bray S, Chabaud S, Dubois T, Diot A, Jordan LB, Thompson AM, Bourdon JC, Perol D, Bouvet P, Diaz JJ, Marcel V. Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes. Cancers (Basel) 2018; 10:cancers10100390. [PMID: 30360377 PMCID: PMC6210205 DOI: 10.3390/cancers10100390] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 10/12/2018] [Accepted: 10/18/2018] [Indexed: 11/16/2022] Open
Abstract
Background: Nucleolin (NCL) is a multifunctional protein with oncogenic properties. Anti-NCL drugs show strong cytotoxic effects, including in triple-negative breast cancer (TNBC) models, and are currently being evaluated in phase II clinical trials. However, few studies have investigated the clinical value of NCL and whether NCL stratified cancer patients. Here, we have investigated for the first time the association of NCL with clinical characteristics in breast cancers independently of the different subtypes. Methods: Using two independent series (n = 216; n = 661), we evaluated the prognostic value of NCL in non-metastatic breast cancers using univariate and/or multivariate Cox-regression analyses. Results: We reported that NCL mRNA expression levels are markers of poor survivals independently of tumour size and lymph node invasion status (n = 216). In addition, an association of NCL expression levels with poor survival was observed in TNBC (n = 40, overall survival (OS) p = 0.0287, disease-free survival (DFS) p = 0.0194). Transcriptomic analyses issued from The Cancer Genome Atlas (TCGA) database (n = 661) revealed that breast tumours expressing either low or high NCL mRNA expression levels exhibit different gene expression profiles. These data suggest that tumours expressing high NCL mRNA levels are different from those expressing low NCL mRNA levels. Conclusions: NCL is an independent marker of prognosis in breast cancers. We anticipated that anti-NCL is a promising therapeutic strategy that could rapidly be evaluated in high NCL-expressing tumours to improve breast cancer management.
Collapse
Affiliation(s)
- Flora Nguyen Van Long
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, CEDEX 08, 69373 Lyon, France; (F.N.V.L.); (P.B.)
| | - Audrey Lardy-Cleaud
- Department of Clinical Research, Léon Bérard Cancer Centre, 28 rue Laennec, 69008 Lyon, France; (A.L.-C.); (S.C.); (D.P.)
| | - Susan Bray
- Tayside Tissue Bank, Ninewells Hospital and Medical School, NHS Tayside, Dundee DD1 9SY, Scotland, UK;
| | - Sylvie Chabaud
- Department of Clinical Research, Léon Bérard Cancer Centre, 28 rue Laennec, 69008 Lyon, France; (A.L.-C.); (S.C.); (D.P.)
| | - Thierry Dubois
- Breast Cancer Biology Group, Translational Research Department, PSL Research University, Institut Curie, 26 rue d’Ulm, 75005 Paris, France;
| | - Alexandra Diot
- Division of Cancer Research, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK; (A.D.); (A.M.T.); (J.-C.B.)
| | - Lee B. Jordan
- Department of Pathology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK;
| | - Alastair M. Thompson
- Division of Cancer Research, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK; (A.D.); (A.M.T.); (J.-C.B.)
- Olga Keith Wiess Chair of Surgery, Dan L. Duncan Breast Center, Division of Surgical Oncology, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jean-Christophe Bourdon
- Division of Cancer Research, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, UK; (A.D.); (A.M.T.); (J.-C.B.)
| | - David Perol
- Department of Clinical Research, Léon Bérard Cancer Centre, 28 rue Laennec, 69008 Lyon, France; (A.L.-C.); (S.C.); (D.P.)
| | - Philippe Bouvet
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, CEDEX 08, 69373 Lyon, France; (F.N.V.L.); (P.B.)
- Ecole Normale Supérieure de Lyon, Université de Lyon, CEDEX 07, 69342 Lyon, France
| | - Jean-Jacques Diaz
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, CEDEX 08, 69373 Lyon, France; (F.N.V.L.); (P.B.)
- Correspondence: (J.-J.D.); (V.M.); Tel.: +33-42655-2819 (J.-J.D.); +33-42655-6745 (V.M.)
| | - Virginie Marcel
- Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, CEDEX 08, 69373 Lyon, France; (F.N.V.L.); (P.B.)
- Correspondence: (J.-J.D.); (V.M.); Tel.: +33-42655-2819 (J.-J.D.); +33-42655-6745 (V.M.)
| |
Collapse
|
13
|
Karni-Schmidt O, Friedler A, Zupnick A, McKinney K, Mattia M, Beckerman R, Bouvet P, Sheetz M, Fersht A, Prives C. Correction: Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene 2018; 37:4901-4902. [PMID: 30068941 DOI: 10.1038/s41388-018-0321-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Following the publication of this article the authors noted that two images were duplicated in Figure 2B. The corrected figure 2B is below. The authors wish to apologize for any inconvenience caused.
Collapse
Affiliation(s)
- O Karni-Schmidt
- Department of Biological Sciences, Columbia University, New York, USA
| | - A Friedler
- Department of MRC-CPE, Center for Protein Engineering, Medical Research Council, Cambridge, UK.,Department of Organic Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem, Israel
| | - A Zupnick
- Department of Biological Sciences, Columbia University, New York, USA
| | - K McKinney
- Department of Biological Sciences, Columbia University, New York, USA
| | - M Mattia
- Department of Biological Sciences, Columbia University, New York, USA
| | - R Beckerman
- Department of Biological Sciences, Columbia University, New York, USA
| | - P Bouvet
- Laboratoire de Biologie Mole´culaire de la Cellule/UMR 5161, Ecole Normale Supe´rieure de Lyon 46, Alle´e d'Italie, 69364, Lyon Cedex, France
| | - M Sheetz
- Department of Biological Sciences, Columbia University, New York, USA
| | - A Fersht
- Department of MRC-CPE, Center for Protein Engineering, Medical Research Council, Cambridge, UK
| | - C Prives
- Department of Biological Sciences, Columbia University, New York, USA.
| |
Collapse
|
14
|
Duret D, Haftek-Terreau Z, Carretier M, Berki T, Ladavière C, Monier K, Bouvet P, Marvel J, Leverrier Y, Charreyre MT, Favier A. Labeling of native proteins with fluorescent RAFT polymer probes: application to the detection of a cell surface protein using flow cytometry. Polym Chem 2018. [DOI: 10.1039/c7py02064c] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Fluorescent RAFT polymer probes with an activated ester reactive end-group can be advantageously used to label native proteins.
Collapse
Affiliation(s)
- D. Duret
- Univ Lyon
- Université Lyon 1
- INSA de Lyon
- CNRS
- Laboratoire Ingénierie des Matériaux Polymères
| | | | - M. Carretier
- Univ Lyon
- Université Lyon 1
- INSA de Lyon
- CNRS
- Laboratoire Ingénierie des Matériaux Polymères
| | - T. Berki
- Univ Lyon
- Université Lyon 1
- INSA de Lyon
- CNRS
- Laboratoire Ingénierie des Matériaux Polymères
| | - C. Ladavière
- Univ Lyon
- Université Lyon 1
- INSA de Lyon
- CNRS
- Laboratoire Ingénierie des Matériaux Polymères
| | - K. Monier
- Univ Lyon
- ENS de Lyon
- CNRS
- Laboratoire Joliot-Curie
- USR3010
| | - P. Bouvet
- Univ Lyon
- ENS de Lyon
- CNRS
- Laboratoire Joliot-Curie
- USR3010
| | - J. Marvel
- Univ Lyon
- INSERM
- ENS de Lyon
- CNRS
- Université Lyon 1
| | | | - M.-T. Charreyre
- Univ Lyon
- Université Lyon 1
- INSA de Lyon
- CNRS
- Laboratoire Ingénierie des Matériaux Polymères
| | - A. Favier
- Univ Lyon
- Université Lyon 1
- INSA de Lyon
- CNRS
- Laboratoire Ingénierie des Matériaux Polymères
| |
Collapse
|
15
|
Posavec Marjanović M, Hurtado-Bagès S, Lassi M, Valero V, Malinverni R, Delage H, Navarro M, Corujo D, Guberovic I, Douet J, Gama-Perez P, Garcia-Roves PM, Ahel I, Ladurner AG, Yanes O, Bouvet P, Suelves M, Teperino R, Pospisilik JA, Buschbeck M. MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD + consumption. Nat Struct Mol Biol 2017; 24:902-910. [PMID: 28991266 PMCID: PMC5791885 DOI: 10.1038/nsmb.3481] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2017] [Accepted: 09/13/2017] [Indexed: 02/06/2023]
Abstract
Histone variants are structural components of eukaryotic chromatin that can replace replication-coupled histones in the nucleosome. The histone variant macroH2A1.1 contains a macrodomain capable of binding NAD+-derived metabolites. Here we report that macroH2A1.1 is rapidly induced during myogenic differentiation through a switch in alternative splicing, and that myotubes that lack macroH2A1.1 have a defect in mitochondrial respiratory capacity. We found that the metabolite-binding macrodomain was essential for sustained optimal mitochondrial function but dispensable for gene regulation. Through direct binding, macroH2A1.1 inhibits basal poly-ADP ribose polymerase 1 (PARP-1) activity and thus reduces nuclear NAD+ consumption. The resultant accumulation of the NAD+ precursor NMN allows for maintenance of mitochondrial NAD+ pools that are critical for respiration. Our data indicate that macroH2A1.1-containing chromatin regulates mitochondrial respiration by limiting nuclear NAD+ consumption and establishing a buffer of NAD+ precursors in differentiated cells.
Collapse
Affiliation(s)
- Melanija Posavec Marjanović
- Programme of Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain
- PhD Program in Biomedicine, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Sarah Hurtado-Bagès
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
- PhD Program in Biomedicine, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain
| | - Maximilian Lassi
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
- German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany
| | - Vanesa Valero
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Roberto Malinverni
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Hélène Delage
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Miriam Navarro
- Metabolomics Platform, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Spain
- Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
| | - David Corujo
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Iva Guberovic
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Julien Douet
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| | - Pau Gama-Perez
- Department of Physiological Sciences II, Faculty of Medicine - University of Barcelona, Spain
| | - Pablo M. Garcia-Roves
- Department of Physiological Sciences II, Faculty of Medicine - University of Barcelona, Spain
| | - Ivan Ahel
- Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
| | - Andreas G. Ladurner
- Biomedical Center Munich (BMC) - Physiological Chemistry, Center for Integrated Protein Science Munich, Munich Cluster for Systems Neurology, Faculty of Medicine, LMU Munich, Planegg-Martinsried, Germany
| | - Oscar Yanes
- Metabolomics Platform, Department of Electronic Engineering (DEEEA), Universitat Rovira i Virgili, Tarragona, Spain
- Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain
| | - Philippe Bouvet
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Mònica Suelves
- Programme of Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain
| | - Raffaele Teperino
- Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany
- German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany
- Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
| | | | - Marcus Buschbeck
- Programme of Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Badalona, Spain
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO-Germans Trias I Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
| |
Collapse
|
16
|
Abstract
Discovered in 1973, nucleolin is one of the most abundant phosphoproteins of the nucleolus. The ability of nucleolin to be involved in many cellular processes is probably related to its structural organization and its capability to form many different interactions with other proteins. Many functions of nucleolin affect cellular processes involved in oncogenesis-for instance: in ribosome biogenesis; in DNA repair, remodeling, and genome stability; in cell division and cell survival; in chemokine and growth factor signaling pathways; in angiogenesis and lymphangiogenesis; in epithelial-mesenchymal transition; and in stemness. In this review, we will describe the different functions of nucleolin in oncogenesis through its interaction with other proteins.
Collapse
Affiliation(s)
- Iva Ugrinova
- "Roumen Tsanev" Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
| | - Maria Petrova
- "Roumen Tsanev" Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria
| | - Mounira Chalabi-Dchar
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, Lyon, France
| | - Philippe Bouvet
- Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| |
Collapse
|
17
|
Motaghi H, Mehrgardi MA, Bouvet P. Carbon Dots-AS1411 Aptamer Nanoconjugate for Ultrasensitive Spectrofluorometric Detection of Cancer Cells. Sci Rep 2017; 7:10513. [PMID: 28874822 PMCID: PMC5585388 DOI: 10.1038/s41598-017-11087-2] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 08/16/2017] [Indexed: 12/26/2022] Open
Abstract
In the present study, a sensitive and selective signal-on method for aptamer based spectrofluorometric detection of cancer cells is introduced. AS1411, a nucleolin aptamer, is wrapped around water-soluble carbon dots and used as a probe for the detection of several types of cancer cells. Nucleolin, is overexpressed on the surface of cancer cells. Mouse breast 4T1, human breast MCF7, and human cervical HeLa cancer cells were selected as target cells, while human foreskin fibroblast cells HFFF-PI6 served as control cells. For the sensitive and selective spectrofluorimetric detection of target cancer cells in the presence of control cells, the cells were incubated in carbon dots-aptamer solutions, the cell suspensions were subsequently centrifuged and the fluorescence intensities were measured as an analytical signal. The specific targeting of cancer cells by AS1411 aptamers causes the release of carbon dots and enhances the fluorescence intensity. A calibration curve with a dynamic range between 10–4500 4T1 cells and detectability of roughly 7 cells was obtained. In addition, no significant change in the signal was detected by modifying the amount of human foreskin fibroblast control cells. Our results demonstrate similar responses to human MCF7 breast and cervical HeLa cancer cells.
Collapse
Affiliation(s)
- Hasan Motaghi
- Department of chemistry, University of Isfahan, Isfahan, 81746-73441, Iran
| | | | - Philippe Bouvet
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France.,Université de Lyon, Ecole Normale Supérieure de 3 Lyon, Lyon, France
| |
Collapse
|
18
|
Kumar S, Gomez EC, Chalabi-Dchar M, Rong C, Das S, Ugrinova I, Gaume X, Monier K, Mongelard F, Bouvet P. Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of Nucleolin. Sci Rep 2017; 7:9017. [PMID: 28827664 PMCID: PMC5567140 DOI: 10.1038/s41598-017-09353-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2017] [Accepted: 07/26/2017] [Indexed: 01/30/2023] Open
Abstract
Nucleolin is an essential protein that plays important roles in the regulation of cell cycle and cell proliferation. Its expression is up regulated in many cancer cells but its molecular functions are not well characterized. Nucleolin is present in the nucleus where it regulates gene expression at the transcriptional and post-transcriptional levels. Using HeLa cells depleted in nucleolin we performed an mRNA and miRNA transcriptomics analysis to identify biological pathways involving nucleolin. Bioinformatic analysis strongly points to a role of nucleolin in lipid metabolism, and in many signaling pathways. Down regulation of nucleolin is associated with lower level of cholesterol while the amount of fatty acids is increased. This could be explained by the decreased and mis-localized expression of the transcription factor SREBP1 and the down-regulation of enzymes involved in the beta-oxidation and degradation of fatty acids. Functional classification of the miRNA-mRNA target genes revealed that deregulated miRNAs target genes involved in apoptosis, proliferation and signaling pathways. Several of these deregulated miRNAs have been shown to control lipid metabolism. This integrated transcriptomic analysis uncovers new unexpected roles for nucleolin in metabolic regulation and signaling pathways paving the way to better understand the global function of nucleolin within the cell.
Collapse
Affiliation(s)
- Sanjeev Kumar
- BioCOS Life Sciences Private Limited, AECS Layout, B-Block, Singasandra Hosur Road SAAMI Building, 851/A, 3rd Floor, Bengaluru, Karnataka, India.
| | - Elizabhet Cruz Gomez
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS, 5286, Centre Léon Bérard, Lyon, France
| | - Mounira Chalabi-Dchar
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS, 5286, Centre Léon Bérard, Lyon, France
| | - Cong Rong
- Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Sadhan Das
- Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Iva Ugrinova
- Institute of Molecular Biology "Acad. Roumen Tsanev" Bulgarian Academy of Sciences "Acad. G Bonchev str. bl. 21, 1113, Sofia, Bulgaria
| | - Xavier Gaume
- Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Karine Monier
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS, 5286, Centre Léon Bérard, Lyon, France
| | - Fabien Mongelard
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS, 5286, Centre Léon Bérard, Lyon, France
- Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France
| | - Philippe Bouvet
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS, 5286, Centre Léon Bérard, Lyon, France.
- Université de Lyon, Ecole Normale Supérieure de Lyon, Lyon, France.
| |
Collapse
|
19
|
Douet J, Corujo D, Malinverni R, Renauld J, Sansoni V, Posavec Marjanović M, Cantariño N, Valero V, Mongelard F, Bouvet P, Imhof A, Thiry M, Buschbeck M. MacroH2A histone variants maintain nuclear organization and heterochromatin architecture. J Cell Sci 2017; 130:1570-1582. [PMID: 28283545 DOI: 10.1242/jcs.199216] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 03/07/2017] [Indexed: 12/15/2022] Open
Abstract
Genetic loss-of-function studies on development, cancer and somatic cell reprogramming have suggested that the group of macroH2A histone variants might function through stabilizing the differentiated state by a yet unknown mechanism. Here, we present results demonstrating that macroH2A variants have a major function in maintaining nuclear organization and heterochromatin architecture. Specifically, we find that a substantial amount of macroH2A is associated with heterochromatic repeat sequences. We further identify macroH2A on sites of interstitial heterochromatin decorated by histone H3 trimethylated on K9 (H3K9me3). Loss of macroH2A leads to major defects in nuclear organization, including reduced nuclear circularity, disruption of nucleoli and a global loss of dense heterochromatin. Domains formed by DNA repeat sequences are disorganized, expanded and fragmented, and mildly re-expressed when depleted of macroH2A. At the molecular level, we find that macroH2A is required for the interaction of repeat sequences with the nucleostructural protein lamin B1. Taken together, our results argue that a major function of macroH2A histone variants is to link nucleosome composition to higher-order chromatin architecture.
Collapse
Affiliation(s)
- Julien Douet
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO - Germans Trias i Pujol, Campus Can Ruti, Badalona 08916, Spain
- Program of Predictive and Personalized Medicine of Cancer, Germans Trias and Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, Badalona 08916, Spain
| | - David Corujo
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO - Germans Trias i Pujol, Campus Can Ruti, Badalona 08916, Spain
- Program of Predictive and Personalized Medicine of Cancer, Germans Trias and Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, Badalona 08916, Spain
| | - Roberto Malinverni
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO - Germans Trias i Pujol, Campus Can Ruti, Badalona 08916, Spain
- Program of Predictive and Personalized Medicine of Cancer, Germans Trias and Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, Badalona 08916, Spain
| | - Justine Renauld
- Cell and tissue biology unit, GIGA-Neurosciences, University of Liege, C.H.U. Sart Tilman, Liege 4000, Belgium
| | - Viola Sansoni
- BioMedical Center and Center for Integrated Protein Sciences Munich, Ludwig-Maximilians-University of Munich, Großhaderner Straße 9, Planegg-Martinsried 82152, Germany
| | - Melanija Posavec Marjanović
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO - Germans Trias i Pujol, Campus Can Ruti, Badalona 08916, Spain
| | - Neus Cantariño
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO - Germans Trias i Pujol, Campus Can Ruti, Badalona 08916, Spain
| | - Vanesa Valero
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO - Germans Trias i Pujol, Campus Can Ruti, Badalona 08916, Spain
- Program of Predictive and Personalized Medicine of Cancer, Germans Trias and Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, Badalona 08916, Spain
| | - Fabien Mongelard
- Université de Lyon, Ecole normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS5286, Centre Léon Bérard, 69008 Lyon, France
| | - Philippe Bouvet
- Université de Lyon, Ecole normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS5286, Centre Léon Bérard, 69008 Lyon, France
| | - Axel Imhof
- BioMedical Center and Center for Integrated Protein Sciences Munich, Ludwig-Maximilians-University of Munich, Großhaderner Straße 9, Planegg-Martinsried 82152, Germany
| | - Marc Thiry
- Cell and tissue biology unit, GIGA-Neurosciences, University of Liege, C.H.U. Sart Tilman, Liege 4000, Belgium
| | - Marcus Buschbeck
- Josep Carreras Leukaemia Research Institute (IJC), Campus ICO - Germans Trias i Pujol, Campus Can Ruti, Badalona 08916, Spain
- Program of Predictive and Personalized Medicine of Cancer, Germans Trias and Pujol Research Institute (PMPPC-IGTP), Campus Can Ruti, Badalona 08916, Spain
| |
Collapse
|
20
|
Wu M, Wei W, Chen J, Cong R, Shi T, Bouvet P, Li J, Wong J, Du JX. Acidic domains differentially read histone H3 lysine 4 methylation status and are widely present in chromatin-associated proteins. Sci China Life Sci 2017; 60:138-151. [PMID: 28194553 DOI: 10.1007/s11427-016-0413-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Accepted: 01/09/2017] [Indexed: 02/03/2023]
Abstract
Histone methylation is believed to provide binding sites for specific reader proteins, which translate histone code into biological function. Here we show that a family of acidic domain-containing proteins including nucleophosmin (NPM1), pp32, SET/TAF1β, nucleolin (NCL) and upstream binding factor (UBF) are novel H3K4me2-binding proteins. These proteins exhibit a unique pattern of interaction with methylated H3K4, as their binding is stimulated by H3K4me2 and inhibited by H3K4me1 and H3K4me3. These proteins contain one or more acidic domains consisting mainly of aspartic and/or glutamic residues that are necessary for preferential binding of H3K4me2. Furthermore, we demonstrate that the acidic domain with sufficient length alone is capable of binding H3K4me2 in vitro and in vivo. NPM1, NCL and UBF require their acidic domains for association with and transcriptional activation of rDNA genes. Interestingly, by defining acidic domain as a sequence with at least 20 acidic residues in 50 continuous amino acids, we identified 655 acidic domain-containing protein coding genes in the human genome and Gene Ontology (GO) analysis showed that many of the acidic domain proteins have chromatin-related functions. Our data suggest that acidic domain is a novel histone binding motif that can differentially read the status of H3K4 methylation and is broadly present in chromatin-associated proteins.
Collapse
Affiliation(s)
- Meng Wu
- Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China
| | - Wei Wei
- Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China
| | - Jiwei Chen
- Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China
| | - Rong Cong
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, Lyon, 69364, France
| | - Tieliu Shi
- Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China
| | - Philippe Bouvet
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, Lyon, 69364, France
- Université de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Jiwen Li
- Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China
| | - Jiemin Wong
- Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
- Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
| | - James X Du
- Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, 200241, China.
| |
Collapse
|
21
|
Marcel V, Catez F, Berger CM, Perrial E, Plesa A, Thomas X, Mattei E, Hayette S, Saintigny P, Bouvet P, Diaz JJ, Dumontet C. Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. PLoS One 2017; 12:e0170160. [PMID: 28103300 PMCID: PMC5245884 DOI: 10.1371/journal.pone.0170160] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Accepted: 12/30/2016] [Indexed: 01/20/2023] Open
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease. Prognosis is mainly influenced by patient age at diagnosis and cytogenetic alterations, two of the main factors currently used in AML patient risk stratification. However, additional criteria are required to improve the current risk classification and better adapt patient care. In neoplastic cells, ribosome biogenesis is increased to sustain the high proliferation rate and ribosome composition is altered to modulate specific gene expression driving tumorigenesis. Here, we investigated the usage of ribosome biogenesis factors as clinical markers in adult patients with AML. We showed that nucleoli, the nucleus compartments where ribosome production takes place, are modified in AML by analyzing a panel of AML and healthy donor cells using immunofluorescence staining. Using four AML series, including the TCGA dataset, altogether representing a total of about 270 samples, we showed that not all factors involved in ribosome biogenesis have clinical values although ribosome biogenesis is increased in AML. Interestingly, we identified the regulator of ribosome production nucleolin (NCL) as over-expressed in AML blasts. Moreover, we found in two series that high NCL mRNA expression level was associated with a poor overall survival, particular in elderly patients. Multivariate analyses taking into account age and cytogenetic risk indicated that NCL expression in blast cells is an independent marker of reduced survival. Our study identifies NCL as a potential novel prognostic factor in AML. Altogether, our results suggest that the ribosome biogenesis pathway may be of interest as clinical markers in AML.
Collapse
MESH Headings
- Adolescent
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/genetics
- Case-Control Studies
- Child
- Child, Preschool
- Female
- Gene Expression Profiling
- Humans
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/metabolism
- Male
- Middle Aged
- Nuclear Proteins/genetics
- Phosphoproteins/genetics
- Prognosis
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- RNA, Neoplasm/genetics
- RNA, Neoplasm/metabolism
- RNA-Binding Proteins/genetics
- Ribosomes/genetics
- Ribosomes/metabolism
- Up-Regulation
- Young Adult
- Nucleolin
Collapse
Affiliation(s)
- Virginie Marcel
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Nuclear domains and pathologies team, Cancer Cell Plasticity Department, Lyon, France
| | - Frédéric Catez
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Nuclear domains and pathologies team, Cancer Cell Plasticity Department, Lyon, France
| | - Caroline M. Berger
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Nuclear domains and pathologies team, Cancer Cell Plasticity Department, Lyon, France
| | - Emeline Perrial
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Anticancer antibodies team, Immunity, Microenvironment and Virus Department, Lyon, France
| | - Adriana Plesa
- Department of Biology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Xavier Thomas
- Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Eve Mattei
- Department of Biology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Sandrine Hayette
- Department of Biology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - Pierre Saintigny
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Department of Medecine, Centre Léon Bérard, Lyon, France
| | - Philippe Bouvet
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Nuclear domains and pathologies team, Cancer Cell Plasticity Department, Lyon, France
- Ecole Normale Supérieure de Lyon, Lyon, France
| | - Jean-Jacques Diaz
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Nuclear domains and pathologies team, Cancer Cell Plasticity Department, Lyon, France
| | - Charles Dumontet
- Cancer Research Center of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
- Université Lyon 1, Lyon, France
- Anticancer antibodies team, Immunity, Microenvironment and Virus Department, Lyon, France
| |
Collapse
|
22
|
Gilles ME, Maione F, Cossutta M, Carpentier G, Caruana L, Di Maria S, Houppe C, Destouches D, Shchors K, Prochasson C, Mongelard F, Lamba S, Bardelli A, Bouvet P, Couvelard A, Courty J, Giraudo E, Cascone I. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Cancer Res 2016; 76:7181-7193. [PMID: 27754848 DOI: 10.1158/0008-5472.can-16-0300] [Citation(s) in RCA: 86] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Revised: 10/05/2016] [Accepted: 10/12/2016] [Indexed: 11/16/2022]
Abstract
Pancreatic cancer is a highly aggressive tumor, mostly resistant to the standard treatments. Nucleolin is overexpressed in cancers and its inhibition impairs tumor growth. Herein, we showed that nucleolin was overexpressed in human specimens of pancreatic ductal adenocarcinoma (PDAC) and that the overall survival significantly increased in patients with low levels of nucleolin. The nucleolin antagonist N6L strongly impaired the growth of primary tumors and liver metastasis in an orthotopic mouse model of PDAC (mPDAC). Similar antitumor effect of N6L has been observed in a highly angiogenic mouse model of pancreatic neuroendocrine tumor RIP-Tag2. N6L significantly inhibited both human and mouse pancreatic cell proliferation and invasion. Notably, the analysis of tumor vasculature revealed a strong increase of pericyte coverage and vessel perfusion both in mPDAC and RIP-Tag2 tumors, in parallel to an inhibition of tumor hypoxia. Nucleolin inhibition directly affected endothelial cell (EC) activation and changed a proangiogenic signature. Among the vascular activators, nucleolin inhibition significantly decreased angiopoietin-2 (Ang-2) secretion and expression in ECs, in the tumor and in the plasma of mPDAC mice. As a consequence of the observed N6L-induced tumor vessel normalization, pre-treatment with N6L efficiently improved chemotherapeutic drug delivery and increased the antitumor properties of gemcitabine in PDAC mice. In conclusion, nucleolin inhibition is a new anti-pancreatic cancer therapeutic strategy that dually blocks tumor progression and normalizes tumor vasculature, improving the delivery and efficacy of chemotherapeutic drugs. Moreover, we unveiled Ang-2 as a potential target and suitable response biomarker for N6L treatment in pancreatic cancer. Cancer Res; 76(24); 7181-93. ©2016 AACR.
Collapse
Affiliation(s)
- Maud-Emmanuelle Gilles
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Federica Maione
- Laboratory of Transgenic Mouse Models, Candiolo Cancer Institute - FPO, IRCCS, Candiolo (TO), Italy
- Department of Science and Drug Technology, University of Torino, Torino, Italy
| | - Mélissande Cossutta
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Gilles Carpentier
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Laure Caruana
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Silvia Di Maria
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Claire Houppe
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Damien Destouches
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Ksenya Shchors
- Swiss Institute for Experimental Cancer Research (ISREC), EPFL SV ISREC, Station 19, Lausanne, Switzerland
| | - Christopher Prochasson
- Department of Pathology, Bichat Hospital APHP DHU UNITY and University of Paris Diderot, Paris, France
| | - Fabien Mongelard
- University of Lyon, Ecole normale Supérieure de Lyon, Cancer Research Center of Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Simona Lamba
- Department of Oncology, University of Torino, Candiolo (TO), Italy
| | - Alberto Bardelli
- Department of Oncology, University of Torino, Candiolo (TO), Italy
- Candiolo Cancer Institute-FPO, IRCCS, Candiolo (TO), Italy
| | - Philippe Bouvet
- University of Lyon, Ecole normale Supérieure de Lyon, Cancer Research Center of Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Anne Couvelard
- Department of Pathology, Bichat Hospital APHP DHU UNITY and University of Paris Diderot, Paris, France
| | - José Courty
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France
| | - Enrico Giraudo
- Laboratory of Transgenic Mouse Models, Candiolo Cancer Institute - FPO, IRCCS, Candiolo (TO), Italy.
- Department of Science and Drug Technology, University of Torino, Torino, Italy
| | - Ilaria Cascone
- University of Paris Est (UPEC), ERL-CNRS 9215, Laboratory of Growth, Reparation and Tissue Regeneration (CRRET), UPEC, Créteil, France.
| |
Collapse
|
23
|
Garcia M, Bouvet P, Petitpas F, Jayle C, Legeay C, Sautereau J, Michaud A, Burucoa C, Plouzeau C. First case report of a human sepsis involving a recently identified anaerobic agent: Bacteroides faecis. Anaerobe 2016; 42:74-77. [PMID: 27544037 DOI: 10.1016/j.anaerobe.2016.08.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2016] [Revised: 08/10/2016] [Accepted: 08/14/2016] [Indexed: 11/17/2022]
Abstract
Up until now, Bacteroides faecis, a Gram-negative, anaerobic, non-motile, nonsporeforming rod has been principally described as a commensal microbe isolated from the feces of healthy adults. We report the first case of human Bacteroides faecis sepsis after removal of suspected post-colonic ischemia colonized epicardic electrodes. Electrodes and blood cultures both grew Gram-negative anaerobic rods but usual phenotypic methods and 16S rARN gene sequencing failed to ensure its species identification. B. faecis was finally identified using hsp60 gene sequencing. Because this species is not well-known and is difficult to identify, it may have been overlooked or misidentified in previous studies.
Collapse
Affiliation(s)
- M Garcia
- Laboratoire de Virologie et Mycobactériologie, CHU de Poitiers, Poitiers, France; EA 4331 LITEC, Université de Poitiers, Poitiers, France.
| | - P Bouvet
- Centre National de Référence des Bactéries anaérobies et du botulisme, Institut Pasteur, Paris, France
| | - F Petitpas
- Service d'Anesthésie et de Réanimation chirurgicale, CHU de Poitiers, Poitiers, France
| | - C Jayle
- Service de Chirurgie Cardio-Thoracique, CHU de Poitiers, Poitiers, France
| | - C Legeay
- Centre National de Référence des Bactéries anaérobies et du botulisme, Institut Pasteur, Paris, France
| | - J Sautereau
- Centre National de Référence des Bactéries anaérobies et du botulisme, Institut Pasteur, Paris, France
| | - A Michaud
- Laboratoire de Bactériologie, CHU de Poitiers, Poitiers, France
| | - C Burucoa
- EA 4331 LITEC, Université de Poitiers, Poitiers, France; Laboratoire de Bactériologie, CHU de Poitiers, Poitiers, France
| | - C Plouzeau
- Laboratoire de Bactériologie, CHU de Poitiers, Poitiers, France; Unité de Microbiologie Moléculaire et Séquençage, CHU de Poitiers, Poitiers, France
| |
Collapse
|
24
|
Swaminathan A, Delage H, Chatterjee S, Belgarbi-Dutron L, Cassel R, Martinez N, Cosquer B, Kumari S, Mongelard F, Lannes B, Cassel JC, Boutillier AL, Bouvet P, Kundu TK. Transcriptional Coactivator and Chromatin Protein PC4 Is Involved in Hippocampal Neurogenesis and Spatial Memory Extinction. J Biol Chem 2016; 291:20303-14. [PMID: 27471272 DOI: 10.1074/jbc.m116.744169] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Indexed: 01/12/2023] Open
Abstract
Although the elaborate combination of histone and non-histone protein complexes defines chromatin organization and hence regulates numerous nuclear processes, the role of chromatin organizing proteins remains unexplored at the organismal level. The highly abundant, multifunctional, chromatin-associated protein and transcriptional coactivator positive coactivator 4 (PC4/Sub1) is absolutely critical for life, because its absence leads to embryonic lethality. Here, we report results obtained with conditional PC4 knock-out (PC4(f/f) Nestin-Cre) mice where PC4 is knocked out specifically in the brain. Compared with the control (PC4(+/+) Nestin-Cre) mice, PC4(f/f) Nestin-Cre mice are smaller with decreased nocturnal activity but are fertile and show no motor dysfunction. Neurons in different areas of the brains of these mice show sensitivity to hypoxia/anoxia, and decreased adult neurogenesis was observed in the dentate gyrus. Interestingly, PC4(f/f) Nestin-Cre mice exhibit a severe deficit in spatial memory extinction, whereas acquisition and long term retention were unaffected. Gene expression analysis of the dorsal hippocampus of PC4(f/f) Nestin-Cre mice revealed dysregulated expression of several neural function-associated genes, and PC4 was consistently found to localize on the promoters of these genes, indicating that PC4 regulates their expression. These observations indicate that non-histone chromatin-associated proteins like PC4 play a significant role in neuronal plasticity.
Collapse
Affiliation(s)
- Amrutha Swaminathan
- From the Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore-560064, India
| | - Hélène Delage
- the Université de Lyon, Ecole Normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Snehajyoti Chatterjee
- the Laboratoire de Neurosciences Cognitives et Adaptatives, UMR7364, Université de Strasbourg, F-67000, Strasbourg, France, the UMR 7364, Laboratoire de Neurosciences Cognitives et Adaptatives, CNRS, F-67000, Strasbourg, France, and
| | | | - Raphaelle Cassel
- the Laboratoire de Neurosciences Cognitives et Adaptatives, UMR7364, Université de Strasbourg, F-67000, Strasbourg, France, the UMR 7364, Laboratoire de Neurosciences Cognitives et Adaptatives, CNRS, F-67000, Strasbourg, France, and
| | - Nicole Martinez
- the Université de Lyon, Ecole Normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Brigitte Cosquer
- the Laboratoire de Neurosciences Cognitives et Adaptatives, UMR7364, Université de Strasbourg, F-67000, Strasbourg, France
| | - Sujata Kumari
- From the Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore-560064, India
| | - Fabien Mongelard
- the Université de Lyon, Ecole Normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Béatrice Lannes
- the Département de Pathologie, Hôpital de Hautepierre, Université de Strasbourg, 67081 Strasbourg, France
| | - Jean-Christophe Cassel
- the Laboratoire de Neurosciences Cognitives et Adaptatives, UMR7364, Université de Strasbourg, F-67000, Strasbourg, France, the UMR 7364, Laboratoire de Neurosciences Cognitives et Adaptatives, CNRS, F-67000, Strasbourg, France, and
| | - Anne-Laurence Boutillier
- the Laboratoire de Neurosciences Cognitives et Adaptatives, UMR7364, Université de Strasbourg, F-67000, Strasbourg, France, the UMR 7364, Laboratoire de Neurosciences Cognitives et Adaptatives, CNRS, F-67000, Strasbourg, France, and
| | - Philippe Bouvet
- the Université de Lyon, Ecole Normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France,
| | - Tapas K Kundu
- From the Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore-560064, India,
| |
Collapse
|
25
|
Marcel V, Van Long FN, Pion N, Erales J, Bourdon J, Puisieux A, Motorine I, Bouvet P, Catez F, Diaz J. Proffered Paper: The rRNA epigenetic hypothesis: role of ribosome heterogeneity in tumorigenesis. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61006-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
26
|
Abstract
Nucleolin is present in diverse cellular compartments and is involved in a variety of cellular processes from nucleolar structure and function to intracellular trafficking, cell adhesion and migration. Recently, nucleolin has been localized at the mature centriole where it is involved in microtubule nucleation and anchoring. Although this new function of nucleolin linked to microtubule regulation has been identified, the global effects of nucleolin on microtubule dynamics have not been addressed yet. In the present study, we analyzed the roles of nucleolin protein levels on global microtubule dynamics by tracking the EB3 microtubule plus end binding protein in live cells. We have found that during microtubule growth phases, nucleolin affects both the speed and life time of polymerization and by analyzing catastrophe events, we showed that nucleolin reduces catastrophe frequency. This new property of nucleolin was then confirmed in a cold induced microtubule depolymerization experiment in which we have found that cold resistant microtubules were totally destabilized in nucleolin depleted cells. Altogether, our data demonstrate a new function of nucleolin on microtubule stabilization, thus bringing novel insights into understanding the multifunctional properties of nucleolin in healthy and cancer cells.
Collapse
Affiliation(s)
- Xavier Gaume
- Université de Lyon, Ecole normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Christophe Place
- Université de Lyon, Ecole Normale Supérieure de Lyon, Université Claude Bernard, CNRS, Laboratoire de Physique, F-69342, Lyon, France
| | - Helene Delage
- Université de Lyon, Ecole normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Fabien Mongelard
- Université de Lyon, Ecole normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Karine Monier
- Université de Lyon, Ecole normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| | - Philippe Bouvet
- Université de Lyon, Ecole normale Supérieure de Lyon, Centre de Recherche en Cancérologie de Lyon, Cancer Cell Plasticity Department, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France
| |
Collapse
|
27
|
Mazuet C, Legeay C, Sautereau J, Ma L, Bouchier C, Bouvet P, Popoff MR. Diversity of Group I and II Clostridium botulinum Strains from France Including Recently Identified Subtypes. Genome Biol Evol 2016; 8:1643-60. [PMID: 27189984 PMCID: PMC4943176 DOI: 10.1093/gbe/evw101] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
In France, human botulism is mainly food-borne intoxication, whereas infant botulism is rare. A total of 99 group I and II Clostridium botulinum strains including 59 type A (12 historical isolates [1947-1961], 43 from France [1986-2013], 3 from other countries, and 1 collection strain), 31 type B (3 historical, 23 recent isolates, 4 from other countries, and 1 collection strain), and 9 type E (5 historical, 3 isolates, and 1 collection strain) were investigated by botulinum locus gene sequencing and multilocus sequence typing analysis. Historical C. botulinum A strains mainly belonged to subtype A1 and sequence type (ST) 1, whereas recent strains exhibited a wide genetic diversity: subtype A1 in orfX or ha locus, A1(B), A1(F), A2, A2b2, A5(B2') A5(B3'), as well as the recently identified A7 and A8 subtypes, and were distributed into 25 STs. Clostridium botulinum A1(B) was the most frequent subtype from food-borne botulism and food. Group I C. botulinum type B in France were mainly subtype B2 (14 out of 20 historical and recent strains) and were divided into 19 STs. Food-borne botulism resulting from ham consumption during the recent period was due to group II C. botulinum B4. Type E botulism is rare in France, 5 historical and 1 recent strains were subtype E3. A subtype E12 was recently identified from an unusual ham contamination. Clostridium botulinum strains from human botulism in France showed a wide genetic diversity and seems to result not from a single evolutionary lineage but from multiple and independent genetic rearrangements.
Collapse
Affiliation(s)
| | - Christine Legeay
- Bactéries Anaérobies et Toxines, Institut Pasteur, Paris, France
| | - Jean Sautereau
- Bactéries Anaérobies et Toxines, Institut Pasteur, Paris, France
| | - Laurence Ma
- Plateforme Genomique-Pôle Biomics, Institut Pasteur, Paris, France
| | | | - Philippe Bouvet
- Bactéries Anaérobies et Toxines, Institut Pasteur, Paris, France
| | - Michel R Popoff
- Bactéries Anaérobies et Toxines, Institut Pasteur, Paris, France
| |
Collapse
|
28
|
Salvetti A, Couté Y, Epstein A, Arata L, Kraut A, Navratil V, Bouvet P, Greco A. Nuclear Functions of Nucleolin through Global Proteomics and Interactomic Approaches. J Proteome Res 2016; 15:1659-69. [PMID: 27049334 DOI: 10.1021/acs.jproteome.6b00126] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Nucleolin (NCL) is a major component of the cell nucleolus, which has the ability to rapidly shuttle to several other cells' compartments. NCL plays important roles in a variety of essential functions, among which are ribosome biogenesis, gene expression, and cell growth. However, the precise mechanisms underlying NCL functions are still unclear. Our study aimed to provide new information on NCL functions via the identification of its nuclear interacting partners. Using an interactomics approach, we identified 140 proteins co-purified with NCL, among which 100 of them were specifically found to be associated with NCL after RNase digestion. The functional classification of these proteins confirmed the prominent role of NCL in ribosome biogenesis and additionally revealed the possible involvement of nuclear NCL in several pre-mRNA processing pathways through its interaction with RNA helicases and proteins participating in pre-mRNA splicing, transport, or stability. NCL knockdown experiments revealed that NCL regulates the localization of EXOSC10 and the amount of ZC3HAV1, two components of the RNA exosome, further suggesting its involvement in the control of mRNA stability. Altogether, this study describes the first nuclear interactome of human NCL and provides the basis for further understanding the mechanisms underlying the essential functions of this nucleolar protein.
Collapse
Affiliation(s)
- Anna Salvetti
- International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308 , 69007 Lyon, France
- Ecole Normale Supérieure de Lyon , 69007 Lyon, France
- Labex Ecofect Université de Lyon , 69007 Lyon, France
| | - Yohann Couté
- Université Grenoble Alpes , 38000 Grenoble, France
- CEA, BIG-BGE , 38000 Grenoble, France
- INSERM, BGE , 38000 Grenoble, France
| | - Alberto Epstein
- International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308 , 69007 Lyon, France
- Ecole Normale Supérieure de Lyon , 69007 Lyon, France
- Labex Ecofect Université de Lyon , 69007 Lyon, France
| | - Loredana Arata
- Subdepartment of Molecular Genetics, Public Health Institute of Chile , Santiago, Chile
| | - Alexandra Kraut
- Université Grenoble Alpes , 38000 Grenoble, France
- CEA, BIG-BGE , 38000 Grenoble, France
- INSERM, BGE , 38000 Grenoble, France
| | - Vincent Navratil
- Pôle Rhône Alpes de Bioinformatique (PRABI), Université Lyon 1 , 69100 Villeurbanne, France
| | - Philippe Bouvet
- Ecole Normale Supérieure de Lyon , 69007 Lyon, France
- Centre de Recherche en Cancérologie de Lyon (CRCL), INSERM U1052, CNRS UMR5286 , 69003 Lyon, France
| | - Anna Greco
- International Center for Infectiology Research (CIRI), Inserm U1111, CNRS UMR5308 , 69007 Lyon, France
- Ecole Normale Supérieure de Lyon , 69007 Lyon, France
| |
Collapse
|
29
|
Mazuet C, Yoon EJ, Boyer S, Pignier S, Blanc T, Doehring I, Meziane-Cherif D, Dumant-Forest C, Sautereau J, Legeay C, Bouvet P, Bouchier C, Quijano-Roy S, Pestel-Caron M, Courvalin P, Popoff MR. A penicillin- and metronidazole-resistant Clostridium botulinum strain responsible for an infant botulism case. Clin Microbiol Infect 2016; 22:644.e7-644.e12. [PMID: 27108966 DOI: 10.1016/j.cmi.2016.04.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Revised: 03/29/2016] [Accepted: 04/08/2016] [Indexed: 11/27/2022]
Abstract
The clinical course of a case of infant botulism was characterized by several relapses despite therapy with amoxicillin and metronidazole. Botulism was confirmed by identification of botulinum toxin and Clostridium botulinum in stools. A C. botulinum A2 strain resistant to penicillins and with heterogeneous resistance to metronidazole was isolated from stool samples up to 110 days after onset. Antibiotic susceptibility was tested by disc agar diffusion and MICs were determined by Etest. Whole genome sequencing allowed detection of a gene cluster composed of blaCBP for a novel penicillinase, blaI for a regulator, and blaR1 for a membrane-bound penicillin receptor in the chromosome of the C. botulinum isolate. The purified recombinant penicillinase was assayed. Resistance to β-lactams was in agreement with the kinetic parameters of the enzyme. In addition, the β-lactamase gene cluster was found in three C. botulinum genomes in databanks and in two of 62 genomes of our collection, all the strains belonging to group I C. botulinum. This is the first report of a C. botulinum isolate resistant to penicillins. This stresses the importance of antibiotic susceptibility testing for adequate therapy of botulism.
Collapse
Affiliation(s)
- C Mazuet
- Unité des Bactéries anaérobies et Toxines, Institut Pasteur, Paris, France
| | - E-J Yoon
- Unité des Agents Antibactériens, Institut Pasteur, Paris, France
| | - S Boyer
- Département de Microbiologie, Hôpital Charles Nicolle, Rouen, France
| | - S Pignier
- Pédiatrie médicale, Hôpital Charles Nicolle, Rouen, France
| | - T Blanc
- Pédiatrie néonatale et réanimation, Hôpital Charles Nicolle, Rouen, France
| | - I Doehring
- AP-HP, Service de Pédiatrie-Réanimation, Pôle Pédiatrique, Hôpital R. Poincaré, Garches, Hôpitaux Universitaires Paris-Ile-de-France Ouest, France
| | - D Meziane-Cherif
- Unité des Agents Antibactériens, Institut Pasteur, Paris, France
| | | | - J Sautereau
- Unité des Bactéries anaérobies et Toxines, Institut Pasteur, Paris, France
| | - C Legeay
- Unité des Bactéries anaérobies et Toxines, Institut Pasteur, Paris, France
| | - P Bouvet
- Unité des Bactéries anaérobies et Toxines, Institut Pasteur, Paris, France
| | - C Bouchier
- Plateforme Genomique-Pôle Biomics, Institut Pasteur, Paris, France
| | - S Quijano-Roy
- AP-HP, Service de Pédiatrie-Réanimation, Pôle Pédiatrique, Hôpital R. Poincaré, Garches, Hôpitaux Universitaires Paris-Ile-de-France Ouest, France; Centre de Référence des Maladies Neuromusculaires GNMH (FILNEMUS), France
| | - M Pestel-Caron
- Département de Microbiologie, Hôpital Charles Nicolle, Rouen, France
| | - P Courvalin
- Unité des Agents Antibactériens, Institut Pasteur, Paris, France
| | - M R Popoff
- Unité des Bactéries anaérobies et Toxines, Institut Pasteur, Paris, France.
| |
Collapse
|
30
|
Jumas-Bilak E, Bouvet P, Allen-Vercoe E, Aujoulat F, Lawson PA, Jean-Pierre H, Marchandin H. Rarimicrobium hominis gen. nov., sp. nov., representing the fifth genus in the phylum Synergistetes that includes human clinical isolates. Int J Syst Evol Microbiol 2015; 65:3965-3970. [PMID: 26320053 DOI: 10.1099/ijsem.0.000520] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Five human clinical isolates of an unknown, strictly anaerobic, slow-growing, Gram-stain-negative, rod-shaped micro-organism were subjected to a polyphasic taxonomic study. Comparative 16S rRNA gene sequence-based phylogeny showed that the isolates grouped in a clade that included members of the genera Pyramidobacter, Jonquetella, and Dethiosulfovibrio; the type strain of Pyramidobacter piscolens was the closest relative with 91.5-91.7 % 16S rRNA gene sequence similarity. The novel strains were mainly asaccharolytic and unreactive in most conventional biochemical tests. Major metabolic end products in trypticase/glucose/yeast extract broth were acetic acid and propionic acid and the major cellular fatty acids were C13 : 0 and C16 : 0, each of which could be used to differentiate the strains from P. piscolens. The DNA G+C content based on whole genome sequencing for the reference strain 22-5-S 12D6FAA was 57 mol%. Based on these data, a new genus, Rarimicrobium gen. nov., is proposed with one novel species, Rarimicrobium hominis sp. nov., named after the exclusive and rare finding of the taxon in human samples. Rarimicrobium is the fifth genus of the 14 currently characterized in the phylum Synergistetes and the third one in subdivision B that includes human isolates. The type strain of Rarimicrobium hominis is ADV70T ( = LMG 28163T = CCUG 65426T).
Collapse
Affiliation(s)
- Estelle Jumas-Bilak
- Université de Montpellier, Unité Mixte de Recherche 5569 - Hydrosciences Montpellier, Equipe Pathogènes Hydriques Santé Environnements, Unité de Bactériologie, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France.,Centre Hospitalier Universitaire de Montpellier, Laboratoire d'Hygiène Hospitalière, 778 rue de la croix verte, 34295 Montpellier Cedex 5, France
| | - Philippe Bouvet
- Institut Pasteur, Centre National de Référence des Bactéries Anaérobies et du Botulisme, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
| | - Emma Allen-Vercoe
- Molecular and Cellular Biology, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada
| | - Fabien Aujoulat
- Université de Montpellier, Unité Mixte de Recherche 5569 - Hydrosciences Montpellier, Equipe Pathogènes Hydriques Santé Environnements, Unité de Bactériologie, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France
| | - Paul A Lawson
- Department of Microbiology and Plant Biology, University of Oklahoma, Norman, OK 73019, USA
| | - Hélène Jean-Pierre
- Université de Montpellier, Unité Mixte de Recherche 5569 - Hydrosciences Montpellier, Equipe Pathogènes Hydriques Santé Environnements, Unité de Bactériologie, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France.,Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Laboratoire de Bactériologie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
| | - Hélène Marchandin
- Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Laboratoire de Bactériologie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.,Université de Montpellier, Unité Mixte de Recherche 5569 - Hydrosciences Montpellier, Equipe Pathogènes Hydriques Santé Environnements, Unité de Bactériologie, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France
| |
Collapse
|
31
|
Abstract
Nucleolin (NCL) is one of the most abundant non ribosomal protein of the nucleolus where it plays a central role in polymerase I transcription. NCL is also found outside of the nucleolus, in the nucleoplasm, cytoplasm as well as on the cell membrane. It acts in all cell compartments to control cellular homeostasis and therefore each cellular pool of NCL can play a different role in cancer development. NCL overexpression and its increased localization at the cell membrane is a common feature of several tumor cells. In cancer cells, NCL overexpression influences cell survival, proliferation and invasion through its action on different cellular pathways. In this review, we describe how the multiple functions of NCL that are associated to its multiple cellular localization can participate to the development of cancer.
Collapse
Affiliation(s)
- Caroline Madeleine Berger
- Département de Biologie, Master Biosciences, ENS de Lyon, Lyon, France; Ecole Normale Supérieure de Lyon, Laboratoire Joliot-Curie, CNRS USR 3010, 46 allée d'Italie, 69364 Lyon Cedex 7, France
| | - Xavier Gaume
- Ecole Normale Supérieure de Lyon, Laboratoire Joliot-Curie, CNRS USR 3010, 46 allée d'Italie, 69364 Lyon Cedex 7, France
| | - Philippe Bouvet
- Ecole Normale Supérieure de Lyon, Laboratoire Joliot-Curie, CNRS USR 3010, 46 allée d'Italie, 69364 Lyon Cedex 7, France.
| |
Collapse
|
32
|
Berthet N, Périchon B, Mazuet C, Chapetón-Montes D, Bouchier C, Bouvet P, Legeay C, Popoff MR, Courvalin P. A vanG-type locus in Clostridium argentinense. J Antimicrob Chemother 2015; 70:1942-5. [PMID: 25802283 DOI: 10.1093/jac/dkv073] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Accepted: 02/24/2015] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES The objective was to study a new vanG-type locus in Clostridium argentinense vanGCar and to determine its impact on glycopeptide susceptibility of the host. METHODS The whole genome of C. argentinense NCIB 10714 was sequenced using Illumina single-reads sequencing technology. The presence of vanGCar in seven C. argentinense strains was tested by PCR and its expression was tested by quantitative RT-PCR (qRT-PCR). Glycopeptide susceptibility was determined by the Etest procedure. RESULTS The vanGCar locus contained four genes encoding a carboxypeptidase, a d-alanine:d-serine ligase, a serine transporter and a serine racemase, and was present in the seven C. argentinense studied. An AraC-type transcriptional regulator was found upstream from the genes. C. argentinense NCIB 10714 was susceptible to vancomycin and to teicoplanin. qRT-PCR experiments revealed that vanGCar was not expressed without or with induction by a subinhibitory concentration of vancomycin. CONCLUSIONS The new vanGCar locus was cryptic in C. argentinense and intrinsic to this species. Emergence of vancomycin resistance in C. argentinense due to decryptification of the vanGCar gene cluster could occur.
Collapse
Affiliation(s)
- Nicolas Berthet
- Centre National de la Recherche Scientifique, UMR3569 Paris, France Centre International de la Recherche Médicale de Franceville, Unité des Zoonoses et Maladies Emergentes, Franceville, Gabon
| | - Bruno Périchon
- Institut Pasteur, Unité des Agents Antibactériens, Paris, France
| | - Christelle Mazuet
- Institut Pasteur, Unité de Recherche et d'Expertise Bactéries Anaérobies et Toxines, Paris, France
| | - Diana Chapetón-Montes
- Institut Pasteur, Unité de Recherche et d'Expertise Bactéries Anaérobies et Toxines, Paris, France
| | | | - Philippe Bouvet
- Institut Pasteur, Unité de Recherche et d'Expertise Bactéries Anaérobies et Toxines, Paris, France
| | - Christine Legeay
- Institut Pasteur, Unité de Recherche et d'Expertise Bactéries Anaérobies et Toxines, Paris, France
| | - Michel-Robert Popoff
- Institut Pasteur, Unité de Recherche et d'Expertise Bactéries Anaérobies et Toxines, Paris, France
| | | |
Collapse
|
33
|
Gaume X, Tassin AM, Ugrinova I, Mongelard F, Monier K, Bouvet P. Centrosomal nucleolin is required for microtubule network organization. Cell Cycle 2015; 14:902-19. [PMID: 25590348 PMCID: PMC4614815 DOI: 10.1080/15384101.2014.1000197] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Revised: 12/11/2014] [Accepted: 12/15/2014] [Indexed: 12/22/2022] Open
Abstract
Nucleolin is a pleiotropic protein involved in a variety of cellular processes. Although multipolar spindle formation has been observed after nucleolin depletion, the roles of nucleolin in centrosome regulation and functions have not been addressed. Here we report using immunofluorescence and biochemically purified centrosomes that nucleolin co-localized only with one of the centrioles during interphase which was further identified as the mature centriole. Upon nucleolin depletion, cells exhibited an amplification of immature centriole markers surrounded by irregular pericentrin staining; these structures were exempt from maturation markers and unable to nucleate microtubules. Furthermore, the microtubule network was disorganized in these cells, exhibiting frequent non-centrosomal microtubules. At the mature centriole a reduced kinetics in the centrosomal microtubule nucleation phase was observed in live silenced cells, as well as a perturbation of microtubule anchoring. Immunoprecipitation experiments showed that nucleolin belongs to protein complexes containing 2 key centrosomal proteins, γ-tubulin and ninein, involved in microtubule nucleation and anchoring steps. Altogether, our study uncovered a new role for nucleolin in restricting microtubule nucleation and anchoring at centrosomes in interphase cells.
Collapse
Affiliation(s)
- Xavier Gaume
- Université de Lyon; Ecole Normale Supérieure de Lyon; CNRS USR 3010; Laboratoire Joliot-Curie; Lyon, France
| | - Anne-Marie Tassin
- Institute for Integrative Biology of the Cell (I2BC); CEA, CNRS, Université Paris Sud; Gif sur Yvette, France
| | - Iva Ugrinova
- Institute of Molecular Biology “Acad. Roumen Tsanev”; Bulgarian Academy of Sciences; Sofia, Bulgaria
| | - Fabien Mongelard
- Université de Lyon; Ecole Normale Supérieure de Lyon; CNRS USR 3010; Laboratoire Joliot-Curie; Lyon, France
| | - Karine Monier
- Université de Lyon; Ecole Normale Supérieure de Lyon; CNRS USR 3010; Laboratoire Joliot-Curie; Lyon, France
| | - Philippe Bouvet
- Université de Lyon; Ecole Normale Supérieure de Lyon; CNRS USR 3010; Laboratoire Joliot-Curie; Lyon, France
| |
Collapse
|
34
|
Genth H, Pauillac S, Schelle I, Bouvet P, Bouchier C, Varela-Chavez C, Just I, Popoff MR. Haemorrhagic toxin and lethal toxin from Clostridium sordellii strain vpi9048: molecular characterization and comparative analysis of substrate specificity of the large clostridial glucosylating toxins. Cell Microbiol 2014; 16:1706-21. [PMID: 24905543 DOI: 10.1111/cmi.12321] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2014] [Revised: 05/12/2014] [Accepted: 05/29/2014] [Indexed: 12/16/2022]
Abstract
Large clostridial glucosylating toxins (LCGTs) are produced by toxigenic strains of Clostridium difficile, Clostridium perfringens, Clostridium novyi and Clostridium sordellii. While most C. sordellii strains solely produce lethal toxin (TcsL), C. sordellii strain VPI9048 co-produces both hemorrhagic toxin (TcsH) and TcsL. Here, the sequences of TcsH-9048 and TcsL-9048 are provided, showing that both toxins retain conserved LCGT features and that TcsL and TcsH are highly related to Toxin A (TcdA) and Toxin B (TcdB) from C. difficile strain VPI10463. The substrate profile of the toxins was investigated with recombinant LCGT transferase domains (rN) and a wide panel of small GTPases. rN-TcsH-9048 and rN-TcdA-10463 glucosylated preferably Rho-GTPases but also Ras-GTPases to some extent. In this respect, rN-TcsH-9048 and rN-TcdA-10463 differ from the respective full-length TcsH-9048 and TcdA-10463, which exclusively glucosylate Rho-GTPases. rN-TcsL-9048 and full length TcsL-9048 glucosylate both Rho- and Ras-GTPases, whereas rN-TcdB-10463 and full length TcdB-10463 exclusively glucosylate Rho-GTPases. Vero cells treated with full length TcsH-9048 or TcdA-10463 also showed glucosylation of Ras, albeit to a lower extent than of Rho-GTPases. Thus, in vitro analysis of substrate spectra using recombinant transferase domains corresponding to the auto-proteolytically cleaved domains, predicts more precisely the in vivo substrates than the full length toxins. Except for TcdB-1470, all LCGTs evoked increased expression of the small GTPase RhoB, which exhibited cytoprotective activity in cells treated with TcsL isoforms, but pro-apoptotic activity in cells treated with TcdA, TcdB, and TcsH. All LCGTs induced a rapid dephosphorylation of pY118-paxillin and of pS144/141-PAK1/2 prior to actin filament depolymerization indicating that disassembly of focal adhesions is an early event leading to the disorganization of the actin cytoskeleton.
Collapse
Affiliation(s)
- Harald Genth
- Institute of Toxicology, Medical School Hannover, Hannover, Germany
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Aujoulat F, Bouvet P, Jumas-Bilak E, Jean-Pierre H, Marchandin H. Veillonella seminalis sp. nov., a novel anaerobic Gram-stain-negative coccus from human clinical samples, and emended description of the genus Veillonella. Int J Syst Evol Microbiol 2014; 64:3526-3531. [PMID: 25052396 DOI: 10.1099/ijs.0.064451-0] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Ten isolates of unknown, Gram-stain-negative, anaerobic cocci were recovered from human clinical samples, mainly from semen. On the basis of their phenotypic features, including morphology, main metabolic end products, gas production, nitrate reduction and decarboxylation of succinate, the strains were identified as members of the genus Veillonella. Multi-locus sequence analysis and corresponding phylogenies were based on 16S rRNA, dnaK and rpoB genes, and on the newly proposed gltA gene. The strains shared high levels of genetic sequence similarity and were related most closely to Veillonella ratti. The strains could not be differentiated from V. ratti on the basis of 16S rRNA gene sequence analysis while gltA, rpoB and dnaK gene sequences showed 85.1, 93.5 and 90.2% similarity with those of the type strain of V. ratti, respectively. Phylogenetic analyses revealed that the isolates formed a robust clade in the V. ratti-Veillonella criceti-Veillonella magna subgroup of the genus Veillonella. As observed for V. criceti, the isolates were able to ferment fructose. In contrast to other members of the genus Veillonella, the 10 strains were not able to metabolize lactate. Cellular fatty acid composition was consistent with that of other species of the genus Veillonella. From these data, the 10 isolates are considered to belong to a novel species in the genus Veillonella, for which the name Veillonella seminalis sp. nov. is proposed. The type strain is ADV 4313.2(T) ( = CIP 107810(T) = LMG 28162(T)). Veillonella strain ACS-216-V-Col6b subjected to whole genome sequencing as part as the Human Microbiome Project is another representative of V. seminalis sp. nov. An emended description of the genus Veillonella is also proposed.
Collapse
Affiliation(s)
- Fabien Aujoulat
- Université Montpellier 1, Unité Mixte de Recherche 5119 Ecosym, Equipe Pathogènes et Environnements, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France
| | - Philippe Bouvet
- Institut Pasteur, Centre National de Référence des Bactéries Anaérobies et du Botulisme, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
| | - Estelle Jumas-Bilak
- Centre Hospitalier Universitaire de Montpellier, Laboratoire d'Hygiène Hospitalière, 778 rue de la Croix Verte, 34295 Montpellier Cedex 5, France.,Université Montpellier 1, Unité Mixte de Recherche 5119 Ecosym, Equipe Pathogènes et Environnements, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France
| | - Hélène Jean-Pierre
- Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Laboratoire de Bactériologie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.,Université Montpellier 1, Unité Mixte de Recherche 5119 Ecosym, Equipe Pathogènes et Environnements, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France
| | - Hélène Marchandin
- Centre Hospitalier Universitaire de Montpellier, Hôpital Arnaud de Villeneuve, Laboratoire de Bactériologie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France.,Université Montpellier 1, Unité Mixte de Recherche 5119 Ecosym, Equipe Pathogènes et Environnements, Faculté de Pharmacie, 15, Avenue Charles Flahault, BP 14491, 34093 Montpellier Cedex 5, France
| |
Collapse
|
36
|
Shandilya J, Senapati P, Hans F, Menoni H, Bouvet P, Dimitrov S, Angelov D, Kundu TK. Centromeric histone variant CENP-A represses acetylation-dependent chromatin transcription that is relieved by histone chaperone NPM1. J Biochem 2014; 156:221-7. [PMID: 24839294 DOI: 10.1093/jb/mvu034] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Mammalian centromeric histone H3 variant, CENP-A, is involved in maintaining the functional integrity and epigenetic inheritance of the centromere. CENP-A causes transcriptional repression of centromeric chromatin through an unknown mechanism. Here, we report that reconstituted CENP-A nucleosomes are amenable to ATP-dependent SWI/SNF-mediated remodelling but are less permissive to acetylation and acetylation-dependent in vitro chromatin transcription. Remarkably, the transcriptional repression of the CENP-A chromatinized template could be relieved by the ectopic addition of histone chaperone, nucleophosmin.
Collapse
Affiliation(s)
- Jayasha Shandilya
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| | - Parijat Senapati
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| | - Fabienne Hans
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| | - Hervé Menoni
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| | - Philippe Bouvet
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| | - Stefan Dimitrov
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| | - Dimitar Angelov
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| | - Tapas K Kundu
- Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore 560064, India; Université Joseph Fourier-Grenoble 1, Institut National de la Santé et de la Recherche Médicale, Institut Albert Bonniot, U823, Site Santé-BP 170, 38042 Grenoble Cedex 9; Université de Lyon, Laboratoire de Biologie Moléculaire de la Cellule, CNRS-UMR 5239, Ecole Normale Supérieure de Lyon, Lyon; and Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France
| |
Collapse
|
37
|
Durut N, Abou-Ellail M, Pontvianne F, Das S, Kojima H, Ukai S, de Bures A, Comella P, Nidelet S, Rialle S, Merret R, Echeverria M, Bouvet P, Nakamura K, Sáez-Vásquez J. A duplicated NUCLEOLIN gene with antagonistic activity is required for chromatin organization of silent 45S rDNA in Arabidopsis. Plant Cell 2014; 26:1330-44. [PMID: 24668745 PMCID: PMC4001387 DOI: 10.1105/tpc.114.123893] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2014] [Revised: 02/24/2014] [Accepted: 03/10/2014] [Indexed: 05/19/2023]
Abstract
In plants as well as in animals, hundreds to thousands of 45S rRNA gene copies localize in Nucleolus Organizer Regions (NORs), and the activation or repression of specific sets of rDNA depends on epigenetic mechanisms. Previously, we reported that the Arabidopsis thaliana nucleolin protein NUC1, an abundant and evolutionarily conserved nucleolar protein in eukaryotic organisms, is required for maintaining DNA methylation levels and for controlling the expression of specific rDNA variants in Arabidopsis. Interestingly, in contrast with animal or yeast cells, plants contain a second nucleolin gene. Here, we report that Arabidopsis NUC1 and NUC2 nucleolin genes are both required for plant growth and survival and that NUC2 disruption represses flowering. However, these genes seem to be functionally antagonistic. In contrast with NUC1, disruption of NUC2 induces CG hypermethylation of rDNA and NOR association with the nucleolus. Moreover, NUC2 loss of function triggers major changes in rDNA spatial organization, expression, and transgenerational stability. Our analyses indicate that silencing of specific rRNA genes is mostly determined by the active or repressed state of the NORs and that nucleolin proteins play a key role in the developmental control of this process.
Collapse
Affiliation(s)
- Nathalie Durut
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| | - Mohamed Abou-Ellail
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| | - Frédéric Pontvianne
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| | - Sadhan Das
- École Normale Supérieure Lyon, CNRS,
Unité de Service et de Recherche 3010, Lyon 69364, France
| | - Hisae Kojima
- Graduate School of Bioagricultural Sciences, Nagoya
University, Nagoya 464-8601, Japan
| | - Seiko Ukai
- Graduate School of Bioagricultural Sciences, Nagoya
University, Nagoya 464-8601, Japan
| | - Anne de Bures
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| | - Pascale Comella
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| | | | | | - Remy Merret
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| | - Manuel Echeverria
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| | - Philippe Bouvet
- École Normale Supérieure Lyon, CNRS,
Unité de Service et de Recherche 3010, Lyon 69364, France
| | - Kenzo Nakamura
- Graduate School of Bioagricultural Sciences, Nagoya
University, Nagoya 464-8601, Japan
| | - Julio Sáez-Vásquez
- CNRS, Laboratoire Génome et Développement
des Plantes, Unité Mixte de Recherche 5096, 66860 Perpignan, France
- Université de Perpignan Via Domitia, Laboratoire
Génome et Développement des Plantes, Unité Mixte de Recherche
5096, F-66860 Perpignan, France
| |
Collapse
|
38
|
Amir I, Bouvet P, Legeay C, Gophna U, Weinberger A. Eisenbergiella tayi gen. nov., sp. nov., isolated from human blood. Int J Syst Evol Microbiol 2014; 64:907-914. [DOI: 10.1099/ijs.0.057331-0] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
A catalase-positive, rod-shaped, non-proteolytic, non-motile, anaerobic bacterial strain, designated B086562T, was isolated from a blood culture of an 84-year-old male patient in Israel. According to 16S rRNA gene sequence phylogeny, this strain has no known close relatives among recognized bacteria but should be placed within the family
Lachnospiraceae
. The most closely related recognized bacteria were from the ‘
Clostridium clostridioforme
group’:
C. clostridioforme
(92.4 %) and
Clostridium bolteae
(92.3 %). The isolate produced butyrate, lactate, acetate and succinate as major metabolic end products. The major fatty acids were C16 : 0 and C18 : 1
cis 9 DMA and the DNA G+C content was 46.0 mol%. On the basis of the phenotypic properties and phylogenetic distinctiveness, the blood isolate represents a novel species of a new genus in the family
Lachnospiraceae
, for which the name Eisenbergiella tayi gen. nov., sp. nov. is proposed. The type strain of Eisenbergiella tayi is B086562T ( = LMG 27400T = DSM 26961T = ATCC BAA-2558T).
Collapse
Affiliation(s)
- Itay Amir
- Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv 69978, Israel
- The Microbiology Laboratory, Ma'ayanei Hayeshua Medical Center, Bnei-Brak 51544, Israel
| | - Philippe Bouvet
- Institut Pasteur, Centre National de Référence des Bactéries Anaérobies et du Botulisme, 25-28 rue du Docteur Roux, F-75724 Paris cedex 15, France
| | - Christine Legeay
- Institut Pasteur, Centre National de Référence des Bactéries Anaérobies et du Botulisme, 25-28 rue du Docteur Roux, F-75724 Paris cedex 15, France
| | - Uri Gophna
- Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat-Aviv, Tel-Aviv 69978, Israel
| | - Abraham Weinberger
- The Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, 69978, Israel
- Department of Internal Medicine, Ma'ayanei Hayeshua Medical Center, Bnei-Brak 51544, Israel
| |
Collapse
|
39
|
Cong R, Das S, Douet J, Wong J, Buschbeck M, Mongelard F, Bouvet P. macroH2A1 histone variant represses rDNA transcription. Nucleic Acids Res 2014; 42:181-92. [PMID: 24071584 PMCID: PMC3874179 DOI: 10.1093/nar/gkt863] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2013] [Revised: 08/30/2013] [Accepted: 09/04/2013] [Indexed: 01/21/2023] Open
Abstract
The regulation of ribosomal DNA transcription is an important step for the control of cell growth. Epigenetic marks such as DNA methylation and posttranslational modifications of canonical histones have been involved in this regulation, but much less is known about the role of histone variants. In this work, we show that the histone variant macroH2A1 is present on the promoter of methylated rDNA genes. The inhibition of the expression of macroH2A1 in human HeLa and HepG2 cells and in a mouse ES cell line resulted in an up to 5-fold increase of pre-rRNA levels. This increased accumulation of pre-rRNA is accompanied by an increase of the loading of RNA polymerase I and UBF on the rDNA without any changes in the number of active rDNA genes. The inhibition of RNA polymerase I transcription by actinomycin D or by knocking down nucleolin, induces the recruitment of macroH2A1 on the rDNA and the relocalization of macroH2A1 in the nucleolus. Interestingly, the inhibition of rDNA transcription induced by nucleolin depletion is alleviated by the inactivation of macroH2A1. These results demonstrate that macroH2A1 is a new factor involved in the regulation of rDNA transcription.
Collapse
Affiliation(s)
- Rong Cong
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona, Barcelona, Spain and The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| | - Sadhan Das
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona, Barcelona, Spain and The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| | - Julien Douet
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona, Barcelona, Spain and The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| | - Jiemin Wong
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona, Barcelona, Spain and The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| | - Marcus Buschbeck
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona, Barcelona, Spain and The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| | - Fabien Mongelard
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona, Barcelona, Spain and The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| | - Philippe Bouvet
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Predictive and Personalized Medicine of Cancer (IMPPC), 08916 Badalona, Barcelona, Spain and The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
| |
Collapse
|
40
|
Popoff MR, Bouvet P. Genetic characteristics of toxigenic Clostridia and toxin gene evolution. Toxicon 2013; 75:63-89. [DOI: 10.1016/j.toxicon.2013.05.003] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 04/30/2013] [Accepted: 05/08/2013] [Indexed: 12/14/2022]
|
41
|
Marcel V, Ghayad S, Belin S, Therizols G, Morel AP, Solano-Gonzàlez E, Vendrell J, Hacot S, Mertani H, Albaret M, Bourdon JC, Jordan L, Thompson A, Tafer Y, Cong R, Bouvet P, Saurin JC, Catez F, Prats AC, Puisieux A, Diaz JJ. p53 acts as a safeguard of translational control by regulating fibrillarin and rRNA methylation in cancer. Cancer Cell 2013; 24:318-30. [PMID: 24029231 PMCID: PMC7106277 DOI: 10.1016/j.ccr.2013.08.013] [Citation(s) in RCA: 206] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2012] [Revised: 07/08/2013] [Accepted: 08/12/2013] [Indexed: 01/01/2023]
Abstract
Ribosomes are specialized entities that participate in regulation of gene expression through their rRNAs carrying ribozyme activity. Ribosome biogenesis is overactivated in p53-inactivated cancer cells, although involvement of p53 on ribosome quality is unknown. Here, we show that p53 represses expression of the rRNA methyl-transferase fibrillarin (FBL) by binding directly to FBL. High levels of FBL are accompanied by modifications of the rRNA methylation pattern, impairment of translational fidelity, and an increase of internal ribosome entry site (IRES)-dependent translation initiation of key cancer genes. FBL overexpression contributes to tumorigenesis and is associated with poor survival in patients with breast cancer. Thus, p53 acts as a safeguard of protein synthesis by regulating FBL and the subsequent quality and intrinsic activity of ribosomes.
Collapse
Affiliation(s)
- Virginie Marcel
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Sandra E. Ghayad
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Stéphane Belin
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Gabriel Therizols
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Anne-Pierre Morel
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Eduardo Solano-Gonzàlez
- Université de Toulouse, UPS, TRADGENE, EA4554, Institut des Maladies Métaboliques et Cardiovasculaires, 1 Avenue Jean Poulhès, BP 84225, F-31432 Toulouse, France
| | - Julie A. Vendrell
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
- ISPB, Faculté de Pharmacie, Université Lyon 1, Lyon, France
- Dundee Cancer Centre, Clinical Research Centre, University of Dundee, Dundee DD1 9SY, UK
| | - Sabine Hacot
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Hichem C. Mertani
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Marie Alexandra Albaret
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | | | - Lee Jordan
- Department of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
| | - Alastair Thompson
- Dundee Cancer Centre, Clinical Research Centre, University of Dundee, Dundee DD1 9SY, UK
| | - Yasmine Tafer
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Rong Cong
- Laboratoire Joliot-Curie, Ecole Normale Supérieure de Lyon, Université de Lyon, CNRS USR 3010, SFR BioSciences UMS3444, Lyon 69364, France
| | - Philippe Bouvet
- Laboratoire Joliot-Curie, Ecole Normale Supérieure de Lyon, Université de Lyon, CNRS USR 3010, SFR BioSciences UMS3444, Lyon 69364, France
| | - Jean-Christophe Saurin
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
- Gastroenterology Unit, Édouard Herriot Hospital, Hospices Civils de Lyon, 69002 Lyon, France
| | - Frédéric Catez
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Anne-Catherine Prats
- Université de Toulouse, UPS, TRADGENE, EA4554, Institut des Maladies Métaboliques et Cardiovasculaires, 1 Avenue Jean Poulhès, BP 84225, F-31432 Toulouse, France
| | - Alain Puisieux
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
| | - Jean-Jacques Diaz
- Centre de Recherche en Cancérologie de Lyon UMR Inserm 1052 CNRS 5286, Centre Léon Bérard, F-69373, Lyon, France
- Université de Lyon, Université Lyon 1, ISPB, Lyon F-69622, France
- Corresponding author
| |
Collapse
|
42
|
Pauillac S, D'allayer J, Lenormand P, Rousselle JC, Bouvet P, Popoff MR. Characterization of the enzymatic activity of Clostridium perfringens TpeL. Toxicon 2013; 75:136-43. [PMID: 23851225 DOI: 10.1016/j.toxicon.2013.07.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2013] [Revised: 06/25/2013] [Accepted: 07/02/2013] [Indexed: 01/01/2023]
Abstract
TpeL is a toxin produced by Clostridium perfringens which belongs to the large clostridial glucosylating toxin family. It was shown that TpeL modifies Ras using UDP-glucose or UDP-N-acetylglucosamine as cosubstrates (Guttenberg et al., 2012; Nagahama et al., 2011). We confirmed that TpeL preferentially glucosaminates the three isoforms of Ras (cH-Ras, N-Ras, and K-Ras) from UDP-N-acetylglucosamine and to a lower extent Rap1a and R-Ras3, and very weakly Rac1. In contrast to previous report, we observed that Ral was not a substrate of TpeL. In addition, we confirmed by in vitro glucosylation and mass spectrometry that TpeL modifies cH-Ras at Thr35.
Collapse
Affiliation(s)
- Serge Pauillac
- Institut Pasteur, Unité des Bactéries anaérobies et Toxines, 25 rue du Dr Roux, 75724 Paris Cedex 15, France
| | | | | | | | | | | |
Collapse
|
43
|
Das S, Cong R, Shandilya J, Senapati P, Moindrot B, Monier K, Delage H, Mongelard F, Kumar S, Kundu TK, Bouvet P. Characterization of nucleolin K88 acetylation defines a new pool of nucleolin colocalizing with pre-mRNA splicing factors. FEBS Lett 2013; 587:417-24. [PMID: 23353999 DOI: 10.1016/j.febslet.2013.01.035] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Revised: 12/17/2012] [Accepted: 01/14/2013] [Indexed: 11/22/2022]
Abstract
Nucleolin is a multifunctional protein that carries several post-translational modifications. We characterized nucleolin acetylation and developed antibodies specific to nucleolin K88 acetylation. Using this antibody we show that nucleolin is acetylated in vivo and is not localized in the nucleoli, but instead is distributed throughout the nucleoplasm. Immunofluorescence studies indicate that acetylated nucleolin is co-localized with the splicing factor SC35 and partially with Y12. Acetylated nucleolin is expressed in all tested proliferating cell types. Our findings show that acetylation defines a new pool of nucleolin which support a role for nucleolin in the regulation of mRNA maturation and transcription by RNA polymerase II.
Collapse
Affiliation(s)
- Sadhan Das
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, Lyon, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
The elementary level of chromatin fiber, namely the nucleofilament, is known to undergo a hierarchical compaction leading to local chromatin loops, then chromatin domains and ultimately chromosome territories. These successive folding levels rely on the formation of chromatin loops ranging from few kb to some Mb. In addition to a packaging and structural role, the high-order organization of genomes functionally impacts on gene expression program. This review summarises to which extent each level of chromatin compaction does affect gene regulation. In addition, we point out the structural and functional changes observed in diseases. Emphasis will be mainly placed on the large-scale organization of the chromatin.
Collapse
Affiliation(s)
- Benoît Moindrot
- Laboratoire Joliot-Curie, Centre National de la Recherche Scientifique (CNRS)/Ecole Normale Supérieure de Lyon, Université de Lyon, 46 allée d'Italie, 69007, Lyon, France
| | | | | |
Collapse
|
45
|
Plassart C, Mauvais F, Heurté J, Sautereau J, Legeay C, Bouvet P. First case of intra-abdominal infection with Clostridium disporicum. Anaerobe 2012; 19:77-8. [PMID: 23247006 DOI: 10.1016/j.anaerobe.2012.12.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2012] [Revised: 11/29/2012] [Accepted: 12/05/2012] [Indexed: 01/03/2023]
Abstract
We describe a case of post-operative intra-abdominal infection with Clostridium disporicum, a gram-positive anaerobic rod rarely isolated in clinical specimens. Its typical doubled-spored form, when present, facilitates its recognition. Phenotype-based identification methods used here were not reliable and a 16S rRNA sequence analysis was needed.
Collapse
Affiliation(s)
- Claire Plassart
- Centre Hospitalier de Beauvais, Avenue Léon Blum BP 40319, 60021 Beauvais cedex, Beauvais, France.
| | | | | | | | | | | |
Collapse
|
46
|
Cong R, Das S, Ugrinova I, Kumar S, Mongelard F, Wong J, Bouvet P. Interaction of nucleolin with ribosomal RNA genes and its role in RNA polymerase I transcription. Nucleic Acids Res 2012; 40:9441-54. [PMID: 22859736 PMCID: PMC3479187 DOI: 10.1093/nar/gks720] [Citation(s) in RCA: 101] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2011] [Revised: 06/04/2012] [Accepted: 07/04/2012] [Indexed: 12/13/2022] Open
Abstract
Nucleolin is a multi-functional nucleolar protein that is required for ribosomal RNA gene (rRNA) transcription in vivo, but the mechanism by which nucleolin modulates RNA polymerase I (RNAPI) transcription is not well understood. Nucleolin depletion results in an increase in the heterochromatin mark H3K9me2 and a decrease in H4K12Ac and H3K4me3 euchromatin histone marks in rRNA genes. ChIP-seq experiments identified an enrichment of nucleolin in the ribosomal DNA (rDNA) coding and promoter region. Nucleolin is preferentially associated with unmethylated rRNA genes and its depletion leads to the accumulation of RNAPI at the beginning of the transcription unit and a decrease in UBF along the coding and promoter regions. Nucleolin is able to affect the binding of transcription termination factor-1 on the promoter-proximal terminator T0, thus inhibiting the recruitment of TIP5 and HDAC1 and the establishment of a repressive heterochromatin state. These results reveal the importance of nucleolin for the maintenance of the euchromatin state and transcription elongation of rDNA.
Collapse
Affiliation(s)
- Rong Cong
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and BioCOS Life Sciences Private Limited, Biotech Park, Electronics City, Phase-1, Bangalore 560100, India
| | - Sadhan Das
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and BioCOS Life Sciences Private Limited, Biotech Park, Electronics City, Phase-1, Bangalore 560100, India
| | - Iva Ugrinova
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and BioCOS Life Sciences Private Limited, Biotech Park, Electronics City, Phase-1, Bangalore 560100, India
| | - Sanjeev Kumar
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and BioCOS Life Sciences Private Limited, Biotech Park, Electronics City, Phase-1, Bangalore 560100, India
| | - Fabien Mongelard
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and BioCOS Life Sciences Private Limited, Biotech Park, Electronics City, Phase-1, Bangalore 560100, India
| | - Jiemin Wong
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and BioCOS Life Sciences Private Limited, Biotech Park, Electronics City, Phase-1, Bangalore 560100, India
| | - Philippe Bouvet
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, 69364 Lyon, France, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China and BioCOS Life Sciences Private Limited, Biotech Park, Electronics City, Phase-1, Bangalore 560100, India
| |
Collapse
|
47
|
Bouvet P, K'Ouas G, Le Coustumier A, Popoff MR. Clostridium celerecrescens, often misidentified as "Clostridium clostridioforme group," is involved in rare human infection cases. Diagn Microbiol Infect Dis 2012; 74:299-302. [PMID: 22901791 DOI: 10.1016/j.diagmicrobio.2012.06.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2012] [Revised: 06/15/2012] [Accepted: 06/25/2012] [Indexed: 11/30/2022]
Abstract
Misidentification of rare Clostridium species often originated from the environment as clinically relevant species is problematic. A strain isolated from a traumatic leg wound first identified as C. clostridioforme was finally identified as the rare Clostridium celerecrescens. Two similar misidentifications are reported in the literature. In order to help the phenotypic differentiation of C. celerecrescens from the close species of the "C. clostridioforme group", an identification table and differential susceptibilities to 4 selected antibiotics are proposed. Once a clinical isolate is referred to this group, identification should be definitively confirmed by unambiguous methods such as 16s rDNA sequencing.
Collapse
Affiliation(s)
- Philippe Bouvet
- Institut Pasteur, Centre National de Référence des Bactéries Anaérobies et du Botulisme, Unité Bactéries anaérobies et Toxines, 25-28 rue du Docteur Roux, F-75724 Paris cedex 15, France.
| | | | | | | |
Collapse
|
48
|
Moindrot B, Audit B, Klous P, Baker A, Thermes C, de Laat W, Bouvet P, Mongelard F, Arneodo A. 3D chromatin conformation correlates with replication timing and is conserved in resting cells. Nucleic Acids Res 2012; 40:9470-81. [PMID: 22879376 PMCID: PMC3479194 DOI: 10.1093/nar/gks736] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Although chromatin folding is known to be of functional importance to control the gene expression program, less is known regarding its interplay with DNA replication. Here, using Circular Chromatin Conformation Capture combined with high-throughput sequencing, we identified megabase-sized self-interacting domains in the nucleus of a human lymphoblastoid cell line, as well as in cycling and resting peripheral blood mononuclear cells (PBMC). Strikingly, the boundaries of those domains coincide with early-initiation zones in every cell types. Preferential interactions have been observed between the consecutive early-initiation zones, but also between those separated by several tens of megabases. Thus, the 3D conformation of chromatin is strongly correlated with the replication timing along the whole chromosome. We furthermore provide direct clues that, in addition to the timing value per se, the shape of the timing profile at a given locus defines its set of genomic contacts. As this timing-related scheme of chromatin organization exists in lymphoblastoid cells, resting and cycling PBMC, this indicates that it is maintained several weeks or months after the previous S-phase. Lastly, our work highlights that the major chromatin changes accompanying PBMC entry into cell cycle occur while keeping largely unchanged the long-range chromatin contacts.
Collapse
Affiliation(s)
- Benoit Moindrot
- Laboratoire Joliot-Curie, Ecole Normale Supérieure de Lyon, CNRS, F-69007 Lyon, France
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Bouvet P, Grégory A, Bellon L, Marmouset C. [Fetal Leptotrichia goodfellowii bacteremia]. Med Mal Infect 2012; 42:174-5. [PMID: 22465058 DOI: 10.1016/j.medmal.2012.02.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2012] [Revised: 02/01/2012] [Accepted: 02/09/2012] [Indexed: 11/29/2022]
|
50
|
Greco A, Arata L, Soler E, Gaume X, Couté Y, Hacot S, Callé A, Monier K, Epstein AL, Sanchez JC, Bouvet P, Diaz JJ. Nucleolin interacts with US11 protein of herpes simplex virus 1 and is involved in its trafficking. J Virol 2012; 86:1449-57. [PMID: 22130536 PMCID: PMC3264372 DOI: 10.1128/jvi.06194-11] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2011] [Accepted: 11/18/2011] [Indexed: 02/06/2023] Open
Abstract
Herpes simplex virus type 1 (HSV-1) infection induces profound nucleolar modifications at the functional and organizational levels, including nucleolar invasion by several viral proteins. One of these proteins is US11, which exhibits several different functions and displays both cytoplasmic localization and clear nucleolar localization very similar to that of the major multifunctional nucleolar protein nucleolin. To determine whether US11 interacts with nucleolin, we purified US11 protein partners by coimmunoprecipitations using a tagged protein, Flag-US11. From extracts of cells expressing Flag-US11 protein, we copurified a protein of about 100 kDa that was further identified as nucleolin. In vitro studies have demonstrated that nucleolin interacts with US11 and that the C-terminal domain of US11, which is required for US11 nucleolar accumulation, is sufficient for interaction with nucleolin. This association was confirmed in HSV-1-infected cells. We found an increase in the nucleolar accumulation of US11 in nucleolin-depleted cells, thereby revealing that nucleolin could play a role in US11 nucleocytoplasmic trafficking through one-way directional transport out of the nucleolus. Since nucleolin is required for HSV-1 nuclear egress, the interaction of US11 with nucleolin may participate in the outcome of infection.
Collapse
Affiliation(s)
- Anna Greco
- Université de Lyon and Université Lyon 1, Lyon, France, and CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Villeurbanne, France
| | - Loredana Arata
- Université de Lyon and Université Lyon 1, Lyon, France, and CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Villeurbanne, France
| | - Eric Soler
- Université de Lyon and Université Lyon 1, Lyon, France, and CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Villeurbanne, France
| | - Xavier Gaume
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, Lyon, France
| | - Yohann Couté
- Geneva Proteomics Center, Central Clinical Chemistry Laboratory, Geneva University Hospital, Genève, Switzerland
| | - Sabine Hacot
- Université de Lyon and Université Lyon 1, Lyon, France, and CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Villeurbanne, France
- CRCL Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Lyon, France
| | - Aleth Callé
- Université de Lyon and Université Lyon 1, Lyon, France, and CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Villeurbanne, France
| | - Karine Monier
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, Lyon, France
| | - Alberto L. Epstein
- Université de Lyon and Université Lyon 1, Lyon, France, and CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Villeurbanne, France
| | - Jean-Charles Sanchez
- Human Protein Sciences, Faculty of Medicine, Geneva University, Geneva, Switzerland
| | - Philippe Bouvet
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS USR 3010, Laboratoire Joliot-Curie, Lyon, France
| | - Jean-Jacques Diaz
- Université de Lyon and Université Lyon 1, Lyon, France, and CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaire et Cellulaire, Villeurbanne, France
- CRCL Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Lyon, France
| |
Collapse
|